QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
(State or other jurisdiction of Incorporation or organization) |
(I.R.S. Employer Identification No.) |
(Address of principal executive offices) |
(Zip Code) |
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
Large accelerated filer |
☐ |
☑ |
||
Non-accelerated filer |
☐ |
Smaller reporting company |
||
Emerging growth company |
Page No. |
||||
PART I—FINANCIAL INFORMATION |
||||
ITEM 1 |
Financial Statements (Unaudited) |
|||
5 |
||||
6 |
||||
7 |
||||
8 |
||||
9 |
||||
10 |
||||
11 |
||||
ITEM 2 |
34 |
|||
ITEM 3 |
47 |
|||
ITEM 4 |
47 |
|||
PART II—OTHER INFORMATION |
||||
ITEM 1 |
48 |
|||
ITEM 1A |
49 |
|||
ITEM 2 |
49 |
|||
ITEM 3 |
49 |
|||
ITEM 4 |
49 |
|||
ITEM 5 |
49 |
|||
ITEM 6 |
50 |
|||
51 |
● | declining sales of tobacco products, and expected continuing decline of sales, in the tobacco industry overall; |
● | our dependence on a small number of third-party suppliers and producers; |
● | the possibility that we will be unable to identify or contract with new suppliers or producers in the event of a supply or product disruption; |
● | the possibility that our licenses to use certain brands or trademarks will be terminated, challenged or restricted; |
● | failure to maintain consumer brand recognition and loyalty of our customers; |
● | our reliance on relationships with several large retailers and national chains for distribution of our products; |
● | uncertainty and continued evolution of markets containing our NewGen products; |
● | intense competition and our ability to compete effectively; |
● | competition from illicit sources; |
● | regulation of our products by the FDA, which has broad regulatory powers; |
● | our products are subject to developing and unpredictable regulation, for example, current court action moving forward certain substantial Pre Market Tobacco Application obligations; |
● | uncertainty related to the regulation and taxation of our NewGen products; |
● | possible significant increases in federal, state and local municipal tobacco- and vapor-related taxes; |
● | sensitivity of end-customers to increased sales taxes and economic conditions; |
● | substantial and increasing U.S. regulation; |
● | possible increasing international control and regulation; |
● | failure to comply with certain regulations; |
● | imposition of significant tariffs on imports into the U.S.; |
● | the scientific community’s lack of information regarding the long-term health effects of certain substances contained in some of our products; |
● | some of our products contain nicotine which is considered to be a highly addictive substance; |
● | contamination of our tobacco supply or products; |
● | requirement to maintain compliance with master settlement agreement escrow account; |
● | our amount of indebtedness; |
● | the terms of our credit facilities, which may restrict our current and future operations; |
● | significant product liability litigation; |
● | reduced disclosure requirements applicable to emerging growth companies may make our common stock less attractive to investors, potentially decreasing our stock price; |
● | failure to maintain our status as an emerging growth company before the five-year maximum time period a company may retain such status; |
● | our principal stockholders will be able to exert significant influence over matters submitted to our stockholders and may take certain actions to prevent takeovers; |
● | our certificate of incorporation and bylaws, as well as Delaware law and certain regulations, could discourage or prohibit acquisition bids or merger proposals, which may adversely affect the market price of our common stock; |
● | our certificate of incorporation limits the ownership of our common stock by individuals and entities that are Restricted Investors. These restrictions may affect the liquidity of our common stock and may result in Restricted Investors being required to sell or redeem their shares at a loss or relinquish their voting, dividend and distribution rights; |
● | our business may be damaged by events outside of our suppliers’ control, such as the impact of epidemics (e.g., coronavirus), political upheavals, or natural disasters; |
● | our reliance on information technology; |
● | security and privacy breaches; |
● | infringement on our intellectual property; |
● | third-party claims that we infringe on their intellectual property; |
● | failure to manage our growth; |
● | failure to successfully integrate our acquisitions or otherwise be unable to benefit from pursuing acquisitions; |
● | fluctuations in our results; |
● | exchange rate fluctuations; |
● | adverse U.S. and global economic conditions; |
● | departure of key management personnel or our inability to attract and retain talent; |
● | future sales of our common stock in the public market could reduce our stock price, and any additional capital raised by us through the sale of equity or convertible securities may dilute your ownership in us; and |
● | we may issue preferred stock whose terms could adversely affect the voting power or value of our common stock. |
ASSETS |
(unaudited) September 30, 2020 |
December 31, 2019 |
||||||
Current assets: |
||||||||
Cash |
$ |
$ |
||||||
Accounts receivable, net of allowances of $ |
||||||||
Inventories |
||||||||
Other current assets |
||||||||
Total current assets |
||||||||
Property, plant, and equipment, net |
||||||||
Right of use assets |
||||||||
Deferred financing costs, net |
||||||||
Goodwill |
||||||||
Other intangible assets, net |
||||||||
Master Settlement Agreement (MSA) escrow deposits |
||||||||
Other assets |
||||||||
Total assets |
$ |
$ |
||||||
LIABILITIES AND STOCKHOLDERS’ EQUITY |
||||||||
Current liabilities: |
||||||||
Accounts payable |
$ |
$ |
||||||
Accrued liabilities |
||||||||
Current portion of long-term debt |
||||||||
Total current liabilities |
||||||||
Notes payable and long-term debt |
||||||||
Deferred income taxes |
||||||||
Lease liabilities |
||||||||
Other long-term liabilities |
||||||||
Total liabilities |
||||||||
Commitments and contingencies |
||||||||
Stockholders’ equity: |
||||||||
Preferred stock; $ |
||||||||
Common stock, voting, $ |
||||||||
Common stock, nonvoting, $ |
||||||||
Additional paid-in capital |
||||||||
Cost of repurchased common stock ( |
( |
) |
||||||
Accumulated other comprehensive loss |
( |
) |
( |
) |
||||
Accumulated earnings (deficit) |
( |
) |
||||||
Total stockholders’ equity |
||||||||
Total liabilities and stockholders’ equity |
$ |
$ |
Three Months Ended September 30, |
||||||||
2020 |
2019 |
|||||||
Net sales |
$ |
$ |
||||||
Cost of sales |
||||||||
Gross profit |
||||||||
Selling, general, and administrative expenses |
||||||||
Operating income |
||||||||
Interest expense, net |
||||||||
Investment income |
( |
) |
( |
) |
||||
Loss on extinguishment of debt |
||||||||
Net periodic cost (income), excluding service cost |
( |
) |
||||||
Income before income taxes |
||||||||
Income tax expense |
||||||||
Consolidated net income |
$ |
$ |
||||||
Basic income per common share: |
||||||||
Consolidated net income |
$ |
$ |
||||||
Diluted income per common share: |
||||||||
Consolidated net income |
$ |
$ |
||||||
Weighted average common shares outstanding: |
||||||||
Basic |
||||||||
Diluted |
Nine Months Ended September 30, |
||||||||
2020 |
2019 |
|||||||
Net sales |
$ |
$ |
||||||
Cost of sales |
||||||||
Gross profit |
||||||||
Selling, general, and administrative expenses |
||||||||
Operating income |
||||||||
Interest expense, net |
||||||||
Investment income |
( |
) |
( |
) |
||||
Loss on extinguishment of debt |
||||||||
Net periodic cost (income), excluding service cost |
( |
) |
||||||
Income before income taxes |
||||||||
Income tax expense |
||||||||
Consolidated net income |
$ |
$ |
||||||
Basic income per common share: |
||||||||
Consolidated net income |
$ |
$ |
||||||
Diluted income per common share: |
||||||||
Consolidated net income |
$ |
$ |
||||||
Weighted average common shares outstanding: |
||||||||
Basic |
||||||||
Diluted |
Three Months Ended September 30, |
||||||||
2020 |
2019 |
|||||||
Consolidated net income |
$ |
$ |
||||||
Other comprehensive income, net of tax |
||||||||
Amortization of unrealized pension and postretirement gain (loss), net of tax of $ |
( |
) |
||||||
Unrealized gain on investments, net of tax of $ |
||||||||
Unrealized gain (loss) on derivative instruments, net of tax of $ |
( |
) |
||||||
Consolidated comprehensive income |
$ |
$ |
Nine Months Ended September 30, |
||||||||
2020 |
2019 |
|||||||
Consolidated net income |
$ |
$ |
||||||
Other comprehensive income (loss), net of tax |
||||||||
Amortization of unrealized pension and postretirement gain (loss), net of tax of $ |
( |
) |
||||||
Unrealized gain on investments, net of tax of $ |
||||||||
Unrealized loss on derivative instruments, net of tax of $ |
( |
) |
( |
) |
||||
( |
) |
|||||||
Consolidated comprehensive income |
$ |
$ |
Nine Months Ended September 30, |
||||||||
2020 |
2019 |
|||||||
Cash flows from operating activities: |
||||||||
Consolidated net income |
$ |
$ |
||||||
Adjustments to reconcile net income to net cash provided by operating activities: |
||||||||
Loss on extinguishment of debt |
||||||||
Pension settlement and curtailment loss |
||||||||
Impairment loss |
||||||||
Loss (gain) on sale of property, plant, and equipment |
( |
) |
||||||
Depreciation expense |
||||||||
Amortization of other intangible assets |
||||||||
Amortization of debt discount and deferred financing costs |
||||||||
Deferred income taxes |
( |
) |
||||||
Stock compensation expense |
||||||||
Noncash lease expense |
||||||||
Changes in operating assets and liabilities: |
||||||||
Accounts receivable |
( |
) |
( |
) |
||||
Inventories |
( |
) |
( |
) |
||||
Other current assets |
( |
) |
( |
) |
||||
Other assets |
||||||||
Accounts payable |
( |
) |
||||||
Accrued postretirement liabilities |
( |
) |
( |
) |
||||
Accrued liabilities and other |
( |
) |
||||||
Net cash provided by operating activities |
$ |
$ |
||||||
Cash flows from investing activities: |
||||||||
Capital expenditures |
$ |
( |
) |
$ |
( |
) |
||
Acquisitions, net of cash acquired |
( |
) |
( |
) |
||||
Restricted cash, MSA deposits |
||||||||
Proceeds on the sale of property, plant and equipment |
||||||||
Payments for investments |
( |
) |
||||||
Net cash (used in) provided by investing activities |
$ |
( |
) |
$ |
||||
Cash flows from financing activities: |
||||||||
Payments of 2018 first lien term loan |
$ |
( |
) |
$ |
( |
) |
||
Payments of 2018 second lien term loan |
( |
) |
||||||
Payments of 2018 revolving credit facility |
( |
) |
||||||
Proceeds from Convertible Senior Notes |
||||||||
Payment of IVG note |
( |
) |
||||||
Proceeds from unsecured note |
||||||||
Standard Diversified Inc. reorganization, net of cash acquired |
( |
) |
||||||
Payment for call options |
( |
) |
||||||
Payment of dividends |
( |
) |
( |
) |
||||
Payments of financing costs |
( |
) |
( |
) |
||||
Exercise of options |
||||||||
Surrender of restricted stock |
( |
) |
||||||
Redemption of options |
( |
) |
||||||
Common stock repurchased |
( |
) |
||||||
Net cash (used in) provided by financing activities |
$ |
( |
) |
$ |
||||
Net (decrease) increase in cash |
$ |
( |
) |
$ |
||||
Cash, beginning of period: |
||||||||
Unrestricted |
||||||||
Restricted |
||||||||
Total cash at beginning of period |
||||||||
Cash, end of period: |
||||||||
Unrestricted |
||||||||
Restricted |
||||||||
Total cash at end of period |
$ |
$ |
||||||
Supplemental schedule of noncash investing activities: |
||||||||
Hold back for acquisition |
$ |
$ |
||||||
Supplemental schedule of noncash financing activities: |
||||||||
Dividends declared not paid |
$ |
$ |
||||||
Issuance of note payable for acquisition |
$ |
$ |
||||||
Accrued expenses for incurred financing costs |
$ |
$ |
Voting Shares |
Common Stock, Voting |
Additional Paid-In Capital |
Cost of Repurchased Common Stock |
Accumulated Other Comprehensive Loss |
Accumulated Earnings (Deficit) |
Total |
||||||||||||||||||||||
Beginning balance July 1, 2020 |
$ |
$ |
$ |
( |
) |
$ |
( |
) |
$ |
( |
) |
$ |
||||||||||||||||
Unrecognized pension and postretirement cost adjustment, net of tax of $ |
- |
|||||||||||||||||||||||||||
Unrealized gain on derivative instruments, net of tax of $ |
- |
|||||||||||||||||||||||||||
Stock compensation expense |
- |
|||||||||||||||||||||||||||
Exercise of options |
||||||||||||||||||||||||||||
Cost of repurchased common stock |
( |
) |
( |
) |
( |
) |
||||||||||||||||||||||
Standard Diversified Inc. reorganization, net |
( |
) |
( |
) |
( |
) |
( |
) |
||||||||||||||||||||
Dividends |
- |
( |
) |
( |
) |
|||||||||||||||||||||||
Net income |
- |
|||||||||||||||||||||||||||
Ending balance September 30, 2020 |
$ |
$ |
$ |
( |
) |
$ |
( |
) |
$ |
$ |
||||||||||||||||||
Beginning balance July 1, 2019 |
$ |
$ |
$ |
$ |
( |
) |
$ |
( |
) |
$ |
||||||||||||||||||
Unrecognized pension and postretirement cost adjustment, net of tax of $ |
- |
( |
) |
( |
) |
|||||||||||||||||||||||
Unrealized gain on MSA investments, net of tax of $ |
- |
|||||||||||||||||||||||||||
Unrealized loss on derivative instruments, net of tax of $ |
- |
( |
) |
( |
) |
|||||||||||||||||||||||
Stock compensation expense |
- |
|||||||||||||||||||||||||||
Restricted stock forfeitures |
||||||||||||||||||||||||||||
Exercise of options |
||||||||||||||||||||||||||||
Dividends |
- |
( |
) |
( |
) |
|||||||||||||||||||||||
Purchase of call options, net of tax of $ |
- |
( |
) |
( |
) |
|||||||||||||||||||||||
Issuance of Convertible Senior Notes, net of tax of $ |
- |
|||||||||||||||||||||||||||
Net income |
- |
|||||||||||||||||||||||||||
Ending balance September 30, 2019 |
$ |
$ |
$ |
$ |
( |
) |
$ |
( |
) |
$ |
Voting Shares |
Common Stock, Voting |
Additional Paid-In Capital |
Cost of Repurchased Common Stock |
Accumulated Other Comprehensive Loss |
Accumulated Earnings (Deficit) |
Total |
||||||||||||||||||||||
Beginning balance January 1, 2020 |
$ |
$ |
$ |
$ |
( |
) |
$ |
( |
) |
$ |
||||||||||||||||||
Unrecognized pension and postretirement cost adjustment, net of tax of $ |
- |
|||||||||||||||||||||||||||
Unrealized loss on derivative instruments, net of tax of $ |
- |
( |
) |
( |
) |
|||||||||||||||||||||||
Stock compensation expense |
- |
|||||||||||||||||||||||||||
Exercise of options |
||||||||||||||||||||||||||||
Cost of repurchased common stock |
( |
) |
( |
) |
( |
) |
||||||||||||||||||||||
Standard Diversified Inc. reorganization, net |
( |
) |
( |
) |
( |
) |
( |
) |
||||||||||||||||||||
Dividends |
- |
( |
) |
( |
) |
|||||||||||||||||||||||
Net income |
- |
|||||||||||||||||||||||||||
Ending balance September 30, 2020 |
$ |
$ |
$ |
( |
) |
$ |
( |
) |
$ |
$ |
||||||||||||||||||
Beginning balance January 1, 2019 |
$ |
$ |
$ |
$ |
( |
) |
$ |
( |
) |
$ |
||||||||||||||||||
Unrecognized pension and postretirement cost adjustment, net of tax of $ |
- |
( |
) |
( |
) |
|||||||||||||||||||||||
Unrealized gain on MSA investments, net of tax of $ |
- |
|||||||||||||||||||||||||||
Unrealized loss on derivative instruments, net of tax of $ |
- |
( |
) |
( |
) |
|||||||||||||||||||||||
Stock compensation expense |
- |
|||||||||||||||||||||||||||
Restricted stock forfeitures |
( |
) |
( |
) |
( |
) |
||||||||||||||||||||||
Exercise of options |
||||||||||||||||||||||||||||
Redemption of options |
- |
( |
) |
( |
) |
|||||||||||||||||||||||
Dividends |
- |
( |
) |
( |
) |
|||||||||||||||||||||||
Purchase of call options, net of tax of $ |
- |
( |
) |
( |
) |
|||||||||||||||||||||||
Issuance of Convertible Senior Notes, net of tax of $ |
- |
|||||||||||||||||||||||||||
Net income |
- |
|||||||||||||||||||||||||||
Ending balance September 30, 2019 |
$ |
$ |
$ |
$ |
( |
) |
$ |
( |
) |
$ |
● | Level 1 – Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets at the measurement date. |
● | Level 2 – Inputs to the valuation methodology include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in inactive markets, inputs other than quoted prices that are observable for the asset or liability, and inputs that are derived principally from or corroborated by observable market data by correlation or other means. |
● | Level 3 – Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. |
Deposits as of |
||||||||
Sales Year |
September 30, 2020 |
December 31, 2019 |
||||||
1999 |
$ |
$ |
||||||
2000 |
||||||||
2001 |
||||||||
2002 |
||||||||
2003 |
||||||||
2004 |
||||||||
2005 |
||||||||
2006 |
||||||||
2007 |
||||||||
2008 |
||||||||
2009 |
||||||||
2010 |
||||||||
2011 |
||||||||
2012 |
||||||||
2013 |
||||||||
2014 |
||||||||
2015 |
||||||||
2016 |
||||||||
2017 |
||||||||
Total |
$ |
$ |
Total consideration transferred |
$ |
|||
Adjustments to consideration transferred: |
||||
Cash acquired |
( |
) |
||
Working capital |
( |
) |
||
Adjusted consideration transferred |
||||
Assets acquired: |
||||
Working capital (primarily AR and inventory) |
||||
Fixed assets and Other long term assets |
||||
Intangible assets |
||||
Other liabilities |
( |
) |
||
Net assets acquired |
$ |
|||
Goodwill |
$ |
September 30, 2020 |
December 31, 2019 |
|||||||
Raw materials and work in process |
$ |
$ |
||||||
Leaf tobacco |
||||||||
Finished goods - Smokeless products |
||||||||
Finished goods - Smoking products |
||||||||
Finished goods - NewGen products |
||||||||
Other |
||||||||
Gross Inventory |
||||||||
LIFO reserve |
( |
) |
( |
) |
||||
Net Inventory |
$ |
$ |
September 30, 2020 |
December 31, 2019 |
|||||||
Inventory deposits |
$ |
$ |
||||||
Insurance deposit |
||||||||
Prepaid taxes |
||||||||
Other |
||||||||
Total |
$ |
$ |
September 30, 2020 |
December 31, 2019 |
|||||||
Land |
$ |
$ |
||||||
Buildings and improvements |
||||||||
Leasehold improvements |
||||||||
Machinery and equipment |
||||||||
Furniture and fixtures |
||||||||
Gross property, plant and equipment |
||||||||
Accumulated depreciation |
( |
) |
( |
) |
||||
Net property, plant and equipment |
$ |
$ |
September 30, 2020 |
December 31, 2019 |
|||||||
Equity investments |
$ |
$ |
||||||
Pension assets |
||||||||
Other |
||||||||
Total |
$ |
$ |
September 30, 2020 |
December 31, 2019 |
|||||||
Accrued payroll and related items |
$ |
$ |
||||||
Customer returns and allowances |
||||||||
Taxes payable |
||||||||
Lease liabilities |
||||||||
Accrued interest |
||||||||
Other |
||||||||
Total |
$ |
$ |
September 30, 2020 |
December 31, 2019 |
|||||||
2018 First Lien Term Loan |
$ |
$ |
||||||
Convertible Senior Notes |
||||||||
Note payable - Promissory Note |
||||||||
Note payable - Unsecured Loan |
||||||||
Note payable - IVG |
||||||||
Gross notes payable and long-term debt |
||||||||
Less deferred finance charges |
( |
) |
( |
) |
||||
Less debt discount |
( |
) |
( |
) |
||||
Less current maturities |
( |
) |
( |
) |
||||
Notes payable and long-term debt |
$ |
$ |
Three Months Ended September 30, |
||||||||
2020 |
2019 |
|||||||
Operating lease cost |
||||||||
Cost of sales |
$ |
$ |
||||||
Selling, general and administrative |
||||||||
Variable lease cost (1) |
||||||||
Short-term lease cost |
||||||||
Sublease income |
( |
) |
( |
) |
||||
Total |
$ |
$ |
(1) |
Nine Months Ended September 30, |
||||||||
2020 |
2019 |
|||||||
Operating lease cost |
||||||||
Cost of sales |
$ |
$ |
||||||
Selling, general and administrative |
||||||||
Variable lease cost (1) |
||||||||
Short-term lease cost |
||||||||
Sublease income |
( |
) |
( |
) |
||||
Total |
$ |
$ |
(1) |
September 30, 2020 |
December 31, 2019 |
|||||||
Assets: |
||||||||
Right of use assets |
$ |
$ |
||||||
Total lease assets |
$ |
$ |
||||||
Liabilities: |
||||||||
Current lease liabilities (2) |
$ |
$ |
||||||
Long-term lease liabilities |
||||||||
Total lease liabilities |
$ |
$ |
(2) |
As of September 30, |
||||||||
2020 |
2019 |
|||||||
Weighted-average remaining lease term - operating leases |
||||||||
Weighted-average discount rate - operating leases |
% |
% |
September 30, 2020 |
December 31, 2019 |
|||||||
2020 |
$ |
$ |
||||||
2021 |
||||||||
2022 |
||||||||
2023 |
||||||||
2024 |
||||||||
Years thereafter |
||||||||
Total lease payments |
$ |
$ |
||||||
Less: Imputed interest |
||||||||
Present value of lease liabilities |
$ |
$ |
Three Months Ended September 30, |
||||||||||||||||
Pension Benefits |
Postretirement Benefits |
|||||||||||||||
2020 |
2019 |
2020 |
2019 |
|||||||||||||
Service cost |
$ |
$ |
$ |
$ |
||||||||||||
Interest cost |
||||||||||||||||
Expected return on plan assets |
( |
) |
||||||||||||||
Amortization of (gains) losses |
( |
) |
||||||||||||||
Settlement and curtailment loss |
||||||||||||||||
Net periodic benefit cost (income) |
$ |
$ |
$ |
$ |
( |
) |
Nine Months Ended September 30, |
||||||||||||||||
Pension Benefits |
Postretirement Benefits |
|||||||||||||||
2020 |
2019 |
2020 |
2019 |
|||||||||||||
Service cost |
$ |
$ |
$ |
$ |
||||||||||||
Interest cost |
||||||||||||||||
Expected return on plan assets |
( |
) |
( |
) |
||||||||||||
Amortization of (gains) losses |
( |
) |
( |
) |
||||||||||||
Settlement and curtailment loss |
||||||||||||||||
Net periodic benefit cost (income) |
$ |
$ |
$ |
( |
) |
$ |
( |
) |
Stock Option Shares |
Weighted Average Exercise Price |
Weighted Average Grant Date Fair Value |
||||||||||
Outstanding, December 31, 2018 |
$ |
$ |
||||||||||
Granted |
||||||||||||
Exercised |
( |
) |
||||||||||
Forfeited |
( |
) |
||||||||||
Outstanding, December 31, 2019 |
||||||||||||
Granted |
||||||||||||
Exercised |
( |
) |
||||||||||
Forfeited |
( |
) |
||||||||||
Outstanding, September 30, 2020 |
$ |
$ |
February 10, 2017 |
May 17, 2017 |
March 7, 2018 |
March 13, 2018 |
March 20, 2019 |
October 24, 2019 |
March 18, 2020 |
||||||||||||||||||||||
Number of options granted |
||||||||||||||||||||||||||||
Options outstanding at September 30, 2020 |
||||||||||||||||||||||||||||
Number exercisable at September 30, 2020 |
||||||||||||||||||||||||||||
Exercise price |
$ |
$ |
$ |
$ |
$ |
$ |
$ |
|||||||||||||||||||||
Remaining lives |
||||||||||||||||||||||||||||
Risk free interest rate |
% |
% |
% |
% |
% |
% |
% |
|||||||||||||||||||||
Expected volatility |
% |
% |
% |
% |
% |
% |
% |
|||||||||||||||||||||
Expected life |
||||||||||||||||||||||||||||
Dividend yield |
% |
% |
% |
% |
% |
|||||||||||||||||||||||
Fair value at grant date |
$ |
$ |
$ |
$ |
$ |
$ |
$ |
March 31, 2017 |
March 7, 2018 |
March 20, 2019 |
March 20, 2019 |
July 19, 2019 |
March 18, 2020 |
|||||||||||||||||||
Number of PRSUs granted |
||||||||||||||||||||||||
PRSUs outstanding at September 30, 2020 |
||||||||||||||||||||||||
Fair value as of grant date |
$ |
$ |
$ |
$ |
$ |
$ |
||||||||||||||||||
Remaining lives |
- |
Three Months Ended September 30, |
||||||||||||||||||||||||
2020 |
2019 |
|||||||||||||||||||||||
Income |
Shares |
Per Share |
Income |
Shares |
Per Share |
|||||||||||||||||||
Consolidated net income |
$ |
$ |
||||||||||||||||||||||
Basic EPS: |
||||||||||||||||||||||||
Weighted average |
$ |
$ |
||||||||||||||||||||||
Diluted EPS: |
||||||||||||||||||||||||
Effect of dilutive securities: |
||||||||||||||||||||||||
Stock options |
||||||||||||||||||||||||
$ |
$ |
Nine Months Ended September 30, |
||||||||||||||||||||||||
2020 |
2019 |
|||||||||||||||||||||||
Income |
Shares |
Per Share |
Income |
Shares |
Per Share |
|||||||||||||||||||
Consolidated net income |
$ |
$ |
||||||||||||||||||||||
Basic EPS: |
||||||||||||||||||||||||
Weighted average |
$ |
$ |
||||||||||||||||||||||
Diluted EPS: |
||||||||||||||||||||||||
Effect of dilutive securities: |
||||||||||||||||||||||||
Stock options |
||||||||||||||||||||||||
$ |
$ |
Three Months Ended September 30, |
||||||||
2020 |
2019 |
|||||||
Net sales |
||||||||
Smokeless products |
$ |
$ |
||||||
Smoking products |
||||||||
NewGen products |
||||||||
Total |
$ |
$ |
||||||
Gross profit |
||||||||
Smokeless products |
$ |
$ |
||||||
Smoking products |
||||||||
NewGen products |
||||||||
Total |
$ |
$ |
||||||
Operating income (loss) |
||||||||
Smokeless products |
$ |
$ |
||||||
Smoking products |
||||||||
NewGen products |
( |
) |
||||||
Corporate unallocated (1) |
( |
) |
( |
) |
||||
Total |
$ |
$ |
||||||
Interest expense, net |
||||||||
Investment income |
( |
) |
( |
) |
||||
Loss on extinguishment of debt |
||||||||
Net periodic cost (income), excluding service cost |
( |
) |
||||||
Income before income taxes |
$ |
$ |
||||||
Capital expenditures |
||||||||
Smokeless products |
$ |
$ |
||||||
Smoking products |
||||||||
NewGen products |
||||||||
Total |
$ |
$ |
||||||
Depreciation and amortization |
||||||||
Smokeless products |
$ |
$ |
||||||
Smoking products |
||||||||
NewGen products |
||||||||
Total |
$ |
$ |
(1) |
Nine Months Ended September 30, |
||||||||
2020 |
2019 |
|||||||
Net sales |
||||||||
Smokeless products |
$ |
$ |
||||||
Smoking products |
||||||||
NewGen products |
||||||||
Total |
$ |
$ |
||||||
Gross profit |
||||||||
Smokeless products |
$ |
$ |
||||||
Smoking products |
||||||||
NewGen products |
||||||||
Total |
$ |
$ |
||||||
Operating income (loss) |
||||||||
Smokeless products |
$ |
$ |
||||||
Smoking products |
||||||||
NewGen products (2) |
||||||||
Corporate unallocated (1) |
( |
) |
( |
) |
||||
Total |
$ |
$ |
||||||
Interest expense, net |
||||||||
Investment income |
( |
) |
( |
) |
||||
Loss on extinguishment of debt |
||||||||
Net periodic cost (income), excluding service cost |
( |
) |
||||||
Income before income taxes |
$ |
$ |
||||||
Capital expenditures |
||||||||
Smokeless products |
$ |
$ |
||||||
Smoking products |
||||||||
NewGen products |
||||||||
Total |
$ |
$ |
||||||
Depreciation and amortization |
||||||||
Smokeless products |
$ |
$ |
||||||
Smoking products |
||||||||
NewGen products |
||||||||
Total |
$ |
$ |
(1) |
(2) |
September 30, 2020 |
December 31, 2019 |
|||||||
Assets |
||||||||
Smokeless products |
$ |
$ |
||||||
Smoking products |
||||||||
NewGen products |
||||||||
Corporate unallocated (1) |
||||||||
Total |
$ |
$ |
(1) |
NewGen Segment |
||||||||
Three Months Ended September 30, |
||||||||
2020 |
2019 |
|||||||
Business to Business |
$ |
$ |
||||||
Business to Consumer - Online |
||||||||
Business to Consumer - Corporate store |
||||||||
Other |
||||||||
Total |
$ |
$ |
NewGen Segment |
||||||||
Nine Months Ended September 30, |
||||||||
2020 |
2019 |
|||||||
Business to Business |
$ |
$ |
||||||
Business to Consumer - Online |
||||||||
Business to Consumer - Corporate store |
||||||||
Other |
||||||||
Total |
$ |
$ |
Three Months Ended September 30, |
||||||||
2020 |
2019 |
|||||||
Domestic |
$ |
$ |
||||||
Foreign |
||||||||
Total |
$ |
$ |
Nine Months Ended September 30, |
||||||||
2020 |
2019 |
|||||||
Domestic |
$ |
$ |
||||||
Foreign |
||||||||
Total |
$ |
$ |
• | Our ability to further penetrate markets with our existing products; |
• | Our ability to introduce new products and product lines that complement our core business; |
• | Decreasing interest in some tobacco products among consumers; |
• | Price sensitivity in our end-markets; |
• | Marketing and promotional initiatives, which cause variability in our results; |
• | General economic conditions, including consumer access to disposable income; |
• | Cost and increasing regulation of promotional and advertising activities; |
• | Cost of complying with regulation, including the “deeming regulations”; |
• | Counterfeit and other illegal products in our end-markets; |
• | Currency fluctuations; |
• | Our ability to identify attractive acquisition opportunities in OTP; and |
• | Our ability to integrate acquisitions. |
Three Months Ended September 30, |
||||||||||||
2020 |
2019 |
% Change |
||||||||||
Consolidated Results of Operations Data: |
||||||||||||
Net sales |
||||||||||||
Smokeless products |
$ |
29,764 |
$ |
26,187 |
13.7 |
% |
||||||
Smoking products |
35,973 |
30,222 |
19.0 |
% |
||||||||
NewGen products |
38,437 |
40,391 |
-4.8 |
% |
||||||||
Total net sales |
104,174 |
96,800 |
7.6 |
% |
||||||||
Cost of sales |
55,867 |
53,984 |
3.5 |
% |
||||||||
Gross profit |
||||||||||||
Smokeless products |
16,042 |
13,587 |
18.1 |
% |
||||||||
Smoking products |
21,263 |
16,619 |
27.9 |
% |
||||||||
NewGen products |
11,002 |
12,610 |
-12.8 |
% |
||||||||
Total gross profit |
48,307 |
42,816 |
12.8 |
% |
||||||||
Selling, general, and administrative expenses |
32,286 |
29,784 |
8.4 |
% |
||||||||
Operating income |
16,021 |
13,032 |
22.9 |
% |
||||||||
Interest expense, net |
5,224 |
3,641 |
43.5 |
% |
||||||||
Investment income |
(3 |
) |
(265 |
) |
-98.9 |
% |
||||||
Loss on extinguishment of debt |
- |
1,158 |
NM |
|||||||||
Net periodic cost (income), excluding service cost |
1,188 |
(12 |
) |
NM |
||||||||
Income before income taxes |
9,612 |
8,510 |
12.9 |
% |
||||||||
Income tax expense |
1,816 |
2,236 |
-18.8 |
% |
||||||||
Consolidated net income |
$ |
7,796 |
$ |
6,274 |
24.3 |
% |
Nine Months Ended September 30, |
||||||||||||
2020 |
2019 |
% Change |
||||||||||
Consolidated Results of Operations Data: |
||||||||||||
Net sales |
||||||||||||
Smokeless products |
$ |
87,081 |
$ |
74,907 |
16.3 |
% |
||||||
Smoking products |
92,290 |
81,104 |
13.8 |
% |
||||||||
NewGen products |
120,455 |
125,756 |
-4.2 |
% |
||||||||
Total net sales |
299,826 |
281,767 |
6.4 |
% |
||||||||
Cost of sales |
161,996 |
157,304 |
3.0 |
% |
||||||||
Gross profit |
||||||||||||
Smokeless products |
46,580 |
39,723 |
17.3 |
% |
||||||||
Smoking products |
53,066 |
43,841 |
21.0 |
% |
||||||||
NewGen products |
38,184 |
40,899 |
-6.6 |
% |
||||||||
Total gross profit |
137,830 |
124,463 |
10.7 |
% |
||||||||
Selling, general, and administrative expenses |
95,436 |
79,455 |
20.1 |
% |
||||||||
Operating income |
42,394 |
45,008 |
-5.8 |
% |
||||||||
Interest expense, net |
15,198 |
11,233 |
35.3 |
% |
||||||||
Investment income |
(128 |
) |
(527 |
) |
-75.7 |
% |
||||||
Loss on extinguishment of debt |
- |
1,308 |
NM |
|||||||||
Net periodic cost (income), excluding service cost |
997 |
(34 |
) |
NM |
||||||||
Income before income taxes |
26,327 |
33,028 |
-20.3 |
% |
||||||||
Income tax expense |
6,029 |
6,989 |
-13.7 |
% |
||||||||
Consolidated net income |
$ |
20,298 |
$ |
26,039 |
-22.0 |
% |
(in thousands) |
Three Months Ended September 30, |
|||||||
2020 |
2019 |
|||||||
Consolidated net income |
$ |
7,796 |
$ |
6,274 |
||||
Add: |
||||||||
Interest expense, net |
5,224 |
3,641 |
||||||
Loss on extinguishment of debt |
- |
1,158 |
||||||
Income tax expense |
1,816 |
2,236 |
||||||
Depreciation expense |
809 |
692 |
||||||
Amortization expense |
477 |
356 |
||||||
EBITDA |
$ |
16,122 |
$ |
14,357 |
||||
Components of Adjusted EBITDA |
||||||||
Other (a) |
1,188 |
151 |
||||||
Stock options, restricted stock, and incentives expense (b) |
772 |
1,314 |
||||||
Transaction expenses (c) |
570 |
470 |
||||||
New product launch costs (d) |
- |
1,979 |
||||||
FDA PMTA (e) |
5,271 |
241 |
||||||
Corporate and vapor restructuring (f) |
- |
265 |
||||||
Adjusted EBITDA |
$ |
23,923 |
$ |
18,777 |
(a) | Represents LIFO adjustment, non-cash pension expense (income) and foreign exchange hedging. |
(b) | Represents non-cash stock options, restricted stock, incentives expense and Solace PRSUs. |
(c) | Represents the fees incurred for transaction expenses. |
(d) | Represents product launch costs for our new product lines. |
(e) | Represents costs associated with applications related to FDA PMTA. |
(f) | Represents costs associated with corporate and vapor restructuring including severance and inventory reserves. |
(in thousands) |
Nine Months Ended September 30, |
|||||||
2020 |
2019 |
|||||||
Consolidated net income |
$ |
20,298 |
$ |
26,039 |
||||
Add: |
||||||||
Interest expense, net |
15,198 |
11,233 |
||||||
Loss on extinguishment of debt |
- |
1,308 |
||||||
Income tax expense |
6,029 |
6,989 |
||||||
Depreciation expense |
2,482 |
1,855 |
||||||
Amortization expense |
1,304 |
1,079 |
||||||
EBITDA |
$ |
45,311 |
$ |
48,503 |
||||
Components of Adjusted EBITDA |
||||||||
Other (a) |
841 |
(25 |
) |
|||||
Stock options, restricted stock, and incentives expense (b) |
1,987 |
3,227 |
||||||
Transaction expenses (c) |
1,909 |
1,567 |
||||||
New product launch costs (d) |
- |
3,691 |
||||||
FDA PMTA (e) |
14,435 |
241 |
||||||
Corporate and vapor restructuring (f) |
- |
1,419 |
||||||
Vendor settlement (g) |
- |
(5,522 |
) |
|||||
Adjusted EBITDA |
$ |
64,483 |
$ |
53,101 |
(a) | Represents LIFO adjustment, non-cash pension expense (income) and foreign exchange hedging. |
(b) | Represents non-cash stock options, restricted stock, incentives expense and Solace PRSUs. |
(c) | Represents the fees incurred for transaction expenses. |
(d) | Represents product launch costs for our new product lines. |
(e) | Represents costs associated with applications related to FDA PMTA. |
(f) | Represents costs associated with corporate and vapor restructuring including severance and inventory reserves. |
(g) | Represents costs associated with settlement of a vendor contract. |
As of |
||||||||
(in thousands) |
September 30, 2020 |
December 31, 2019 |
||||||
Current assets |
$ |
170,472 |
$ |
189,250 |
||||
Current liabilities |
54,967 |
55,886 |
||||||
Working capital |
$ |
115,505 |
$ |
133,364 |
September 30, 2020 |
December 31, 2019 |
|||||||
2018 First Lien Term Loan |
$ |
138,000 |
$ |
146,000 |
||||
Convertible Senior Notes |
172,500 |
172,500 |
||||||
Note payable - Promissory Note |
10,000 |
- |
||||||
Note payable - Unsecured Loan |
7,485 |
- |
||||||
Note payable - IVG |
- |
4,240 |
||||||
Gross notes payable and long-term debt |
327,985 |
322,740 |
||||||
Less deferred finance charges |
(5,360 |
) |
(6,466 |
) |
||||
Less debt discount |
(26,833 |
) |
(32,083 |
) |
||||
Less current maturities |
(12,000 |
) |
(15,240 |
) |
||||
Notes payable and long-term debt |
$ |
283,792 |
$ |
268,951 |
Period |
Total Number of Shares Purchased |
Average Price Paid per Share |
Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs |
Maximum Number (or Approximate Dollar Value) of Shares that May Yet Be Purchased Under the Plans or Programs |
||||||||||||
July 1 to July 31 |
- |
$ |
- |
- |
44,710,727 |
|||||||||||
August 1 to August 31 |
52,630 |
$ |
28.97 |
52,630 |
43,186,036 |
|||||||||||
September 1 to September 30 |
29,467 |
$ |
28.91 |
29,467 |
42,334,145 |
|||||||||||
Total |
82,097 |
82,097 |
Exhibit No. |
Description |
Agreement and Plan of Merger and Reorganization, dated as of April 7, 2020, by and among TPB, SDI and Merger Sub (incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K filed on April 8, 2020). |
|
Turning Point Brands, Inc. Second Amended and Restated Bylaws.* |
|
Release and Severance Agreement, dated August 19, 2020, by and among TPB and James W. Dobbins, Senior Vice President and General Counsel.* |
|
Consulting Agreement dated August 19, 2020, but effective November 1, 2020, between Turning Point Brands, Inc. and James Dobbins* |
|
Rule 13a-14(a)/15d-14(a) Certification of Lawrence S. Wexler.* |
|
Rule 13a-14(a)/15d-14(a) Certification of Robert Lavan.* |
|
Rule 13a-14(a)/15d-14(a) Certification of Brian Wigginton.* |
|
Section 1350 Certifications pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.* |
|
101 |
XBRL (eXtensible Business Reporting Language). The following materials from Turning Point Brands, Inc.’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, filed on October 27, 2020, formatted in Inline XBRL (iXBRL): (i) consolidated balance sheets, (ii) consolidated statements of income, (iii) consolidated statements of comprehensive income, (iv) consolidated statements of cash flows, and (v) the notes to consolidated financial statements.* |
104 |
Cover Page Interactive Data File (formatted in iXBRL and included in Exhibit 101).* |
TURNING POINT BRANDS, INC. |
||||
By: /s/ Lawrence S. Wexler |
||||
Name: Lawrence S. Wexler |
||||
Title: President and Chief Executive Officer |
||||
By: /s/ Robert Lavan |
||||
Name: Robert Lavan |
||||
Title: Chief Financial Officer |
||||
By: /s/ Brian Wigginton |
||||
Name: Brian Wigginton |
||||
Title: Chief Accounting Officer |
A. |
Employee and Turning Point are parties to an Employment Letter, dated as of November 23, 2015 (the "Employment Agreement"), which provides for severance after
termination in certain circumstances, conditioned upon Employee first signing a general release of claims following termination of Employee's employment, which release becomes irrevocable in accordance with its terms.
|
B. |
This Release is the contemplated release of claims under the Employment Agreement of which Employee has had notice since the Employment Agreement was executed, it being annexed thereto (the "Presentation
Date").
|
C. |
Employee's employment with the Company will end on October 31, 2020 (the "Separation Date").
|
D. |
The Parties desire to settle any and all other claims, if any, that Employee may have against the Company or any of its employees that are releasable by law.
|
/s/ James W. Dobbins
|
||
James W. Dobbins
|
||
Date:
|
8/19/2020 | |
-- and --
|
||
TURNING POINT BRANDS, INC.
|
||
By:
|
/s/ Lawrence S. Wexler
|
|
Title:
|
President and Chief Executive Officer
|
|
Date:
|
8/19/2020
|
Turning Point Brands, Inc. | |||
/s/ James W. Dobbins
|
By:
|
/s/ Lawrence S. Wexler
|
James W. Dobbins
|
Lawrence S. Wexler
|
|||
Turning Point Brands, Inc.
|
||||
Date:
|
8/19/2020
|
Date:
|
8/19/2020
|
Date: October 27, 2020
|
By:
|
/s/ Lawrence S. Wexler
|
Lawrence S. Wexler
|
||
President and Chief Executive Officer
|
||
(Principal Executive Officer)
|
Date: October 27, 2020
|
By:
|
/s/ Robert Lavan
|
Robert Lavan
|
||
Chief Financial Officer
|
||
(Principal Financial Officer)
|
Date: October 27, 2020
|
By:
|
/s/ Brian Wigginton
|
Brian Wigginton
|
||
Chief Accounting Officer
|
Date: October 27, 2020
|
By:
|
/s/ Lawrence S. Wexler
|
Lawrence S. Wexler
|
||
President and Chief Executive Officer
|
||
(Principal Executive Officer)
|
Date: October 27, 2020
|
By:
|
/s/ Robert Lavan
|
Robert Lavan
|
||
Chief Financial Officer
|
||
(Principal Financial Officer)
|
Date: October 27, 2020
|
By:
|
/s/ Brian Wigginton
|
Brian Wigginton
|
||
Chief Accounting Officer
|
Consolidated Statements of Income (unaudited) - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2020 |
Sep. 30, 2019 |
Sep. 30, 2020 |
Sep. 30, 2019 |
|
Consolidated Statements of Income (unaudited) [Abstract] | ||||
Net sales | $ 104,174 | $ 96,800 | $ 299,826 | $ 281,767 |
Cost of sales | 55,867 | 53,984 | 161,996 | 157,304 |
Gross profit | 48,307 | 42,816 | 137,830 | 124,463 |
Selling, general, and administrative expenses | 32,286 | 29,784 | 95,436 | 79,455 |
Operating income | 16,021 | 13,032 | 42,394 | 45,008 |
Interest expense, net | 5,224 | 3,641 | 15,198 | 11,233 |
Investment income | (3) | (265) | (128) | (527) |
Loss on extinguishment of debt | 0 | 1,158 | 0 | 1,308 |
Net periodic cost (income), excluding service cost | 1,188 | (12) | 997 | (34) |
Income before income taxes | 9,612 | 8,510 | 26,327 | 33,028 |
Income tax expense | 1,816 | 2,236 | 6,029 | 6,989 |
Consolidated net income | $ 7,796 | $ 6,274 | $ 20,298 | $ 26,039 |
Basic income per common share: | ||||
Consolidated net income (in dollars per share) | $ 0.41 | $ 0.32 | $ 1.04 | $ 1.33 |
Diluted income per common share: | ||||
Consolidated net income (in dollars per share) | $ 0.40 | $ 0.31 | $ 1.02 | $ 1.32 |
Weighted average common shares outstanding: | ||||
Basic (in shares) | 19,240,187 | 19,659,217 | 19,478,297 | 19,613,868 |
Diluted (in shares) | 19,636,989 | 20,067,413 | 19,858,691 | 19,777,163 |
Consolidated Statements of Comprehensive Income (unaudited) - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2020 |
Sep. 30, 2019 |
Sep. 30, 2020 |
Sep. 30, 2019 |
|
Consolidated Statements of Comprehensive Income (unaudited) [Abstract] | ||||
Consolidated net income | $ 7,796 | $ 6,274 | $ 20,298 | $ 26,039 |
Other comprehensive income (loss), net of tax | ||||
Amortization of unrealized pension and postretirement gain (loss), net of tax | 1,816 | (4) | 1,830 | (11) |
Unrealized gain on investments, net of tax | 0 | 263 | 0 | 1,174 |
Unrealized gain (loss) on derivative instruments, net of tax | 238 | (208) | (1,302) | (1,616) |
Other comprehensive income (loss), net of tax | 2,054 | 51 | 528 | (453) |
Consolidated comprehensive income | $ 9,850 | $ 6,325 | $ 20,826 | $ 25,586 |
Consolidated Statements of Comprehensive Income (unaudited) (Parenthetical) - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2020 |
Sep. 30, 2019 |
Sep. 30, 2020 |
Sep. 30, 2019 |
|
Other comprehensive income (loss), net of tax | ||||
Amortization of unrealized pension and postretirement gain (loss), tax | $ 62 | $ 1 | $ 57 | $ 4 |
Unrealized gain on investments, tax | 0 | 88 | 0 | 351 |
Unrealized gain (loss) on derivative instruments, tax | $ 84 | $ 70 | $ 516 | $ 563 |
Consolidated Statements of Changes in Stockholders' Equity (Deficit) (unaudited) (Parenthetical) - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended |
---|---|---|
Sep. 30, 2019 |
Sep. 30, 2019 |
|
Consolidated Statements of Changes in Stockholders' Equity (Deficit) (unaudited) [Abstract] | ||
Unrecognized pension and postretirement cost adjustment, tax | $ 1 | $ 4 |
Unrealized gain on MSA investments, tax | 88 | 351 |
Unrealized gain (loss) on derivative instruments, tax | 70 | 563 |
Purchase of call options, tax | 5,091 | 5,091 |
Issuance of Convertible Senior Notes, tax | $ 778 | $ 778 |
Description of Business and Basis of Presentation |
9 Months Ended |
---|---|
Sep. 30, 2020 | |
Description of Business and Basis of Presentation [Abstract] | |
Description of Business and Basis of Presentation |
Note 1. Description of Business and Basis of Presentation
Description of Business
Turning Point Brands, Inc. and its Subsidiaries (collectively referred to herein as the “Company,” “we,” “our,” or “us”) is a leading manufacturer, marketer and distributor of branded consumer products with active ingredients. We sell a wide range of products to adult consumers, from our iconic brands to our next generation products to fulfill evolving consumer preferences. Our three focus segments are led by our core, proprietary brands – Stoker’s® in Smokeless Products; Zig-Zag® in Smoking Products; and Nu-X®, Solace® along with our distribution platforms (VaporBeast®, VaporFi® and Direct Vapor®) in NewGen. The Company’s products are available in more than 210,000 retail outlets in North America. We operate in three segments: (i) Smokeless products, (ii) Smoking products, and (iii) NewGen products.
Basis of Presentation
The accompanying unaudited interim, consolidated financial statements have been prepared in accordance with the accounting practices described in the Company’s audited, consolidated financial statements as of and for the year ended December 31, 2019. In the opinion of management, the unaudited, interim, consolidated financial statements included herein contain all adjustments necessary to present fairly the financial position, results of operations, and cash flows of the Company for the periods indicated. Such adjustments, other than nonrecurring adjustments separately disclosed, are of a normal and recurring nature. The operating results for interim periods are not necessarily indicative of results to be expected for a full year or future interim periods. The unaudited, interim, consolidated financial statements should be read in conjunction with the Company’s audited, consolidated financial statements and accompanying notes as of and for the year ended December 31, 2019. The accompanying interim, consolidated financial statements are presented in accordance with the rules and regulations of the Securities and Exchange Commission and, accordingly, do not include all the disclosures required by generally accepted accounting principles in the United States (“GAAP”) with respect to annual financial statements.
Certain prior year amounts have been reclassified to conform to the current year’s presentation. The changes did not have an impact on the Company’s consolidated financial position, results of operations, or cash flows in any of the periods presented.
|
Summary of Significant Accounting Policies |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2020 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of Significant Accounting Policies [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of Significant Accounting Policies |
Note 2. Summary of Significant Accounting Policies
Consolidation
The consolidated financial statements include the accounts of the Company and its subsidiaries, all of which are wholly-owned. All significant intercompany transactions have been eliminated.
Revenue Recognition
The Company recognizes revenues in accordance with Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (Topic 606), which includes excise taxes and shipping and handling charges billed to customers, net of cash discounts for prompt payment, sales returns and incentives, upon delivery of goods to the customer – at which time the Company’s performance obligation is satisfied – at an amount that the Company expects to be entitled to in exchange for those goods in accordance with the five-step analysis outlined in Topic 606: (i) identify the contract with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations, and (v) recognize revenue when (or as) performance obligations are satisfied. The Company excludes from the transaction price, sales taxes and value-added taxes imposed at the time of sale (which do not include excise taxes on smokeless tobacco, cigars or vaping products billed to customers).
The Company records an allowance for sales returns, based principally on historical volume and return rates, which is included in accrued liabilities on the consolidated balance sheets. The Company records sales incentives, which consist of consumer incentives and trade promotion activities, as a reduction in revenues (a portion of which is based on amounts estimated as being due to wholesalers, retailers and consumers at the end of the period) based principally on historical volume and utilization rates. Expected payments for sales incentives are included in accrued liabilities on the consolidated balance sheets.
A further requirement of ASU 2014-09 is for entities to disaggregate revenue recognized from contracts with customers into categories that depict how the nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factors. Company management views business performance through segments that closely resemble the performance of major product lines. Thus, the primary and most useful disaggregation of the Company’s contract revenue for decision making purposes is the disaggregation by segment which can be found in Note 18 of Notes to Consolidated Financial Statements. An additional disaggregation of contract revenue by sales channel can be found within Note 18 as well.
Shipping Costs
The Company records shipping costs incurred as a component of selling, general, and administrative expenses. Shipping costs incurred were approximately $5.3 million and $4.4 million for the three months ending September 30, 2020 and 2019, respectively. Shipping costs incurred were approximately $17.4 million and $13.6 million for the nine months ending September 30, 2020 and 2019, respectively.
Fair Value
GAAP establishes a framework for measuring fair value. That framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1) and the lowest priority to unobservable inputs (level 3).
The three levels of the fair value hierarchy under GAAP are described below:
Derivative Instruments
Foreign Currency Forward Contracts: The Company enters into foreign currency forward contracts to hedge a portion of its exposure to changes in foreign currency exchange rates on inventory purchase commitments. The Company accounts for its forward contracts under the provisions of ASC 815, Derivatives and Hedging. Under the Company’s policy, the Company may hedge up to 100% of its anticipated purchases of inventory in the denominated invoice currency over a forward period not to exceed twelve months. The Company may also, from time to time, hedge up to ninety percent of its non-inventory purchases in the denominated invoice currency. Forward contracts that qualify as hedges are adjusted to their fair value through other comprehensive income as determined by market prices on the measurement date, except any hedge ineffectiveness which is recognized currently in income. Gains and losses on these forward contracts are transferred from other comprehensive income into inventory as the related inventories are received and are transferred to net income as inventory is sold. Changes in fair value of any contracts that do not qualify for hedge accounting or are not designated as hedges are recognized currently in income.
Interest Rate Swap Agreements: The Company enters into interest rate swap contracts to manage interest rate risk and reduce the volatility of future cash flows. The Company accounts for its interest rate swap contracts under the provisions of ASC 815, Derivatives and Hedging. Swap contracts that qualify as hedges are adjusted to their fair value through other comprehensive income as determined by market prices on the measurement date, except any hedge ineffectiveness which is recognized currently in income. Gains and losses on these swap contracts are transferred from other comprehensive income into net income upon settlement of the derivative position or at maturity of the interest rate swap contract. Changes in fair value of any contracts that do not qualify for hedge accounting or are not designated as hedges are recognized currently in income.
Risks and Uncertainties
Manufacturers and sellers of tobacco products are subject to regulation at the federal, state, and local levels. Such regulations include, among others, labeling requirements, limitations on advertising, and prohibition of sales to minors. The tobacco industry is likely to continue to be heavily regulated. There can be no assurance as to the ultimate content, timing, or effect of any regulation of tobacco products by any federal, state, or local legislative or regulatory body, nor can there be any assurance that any such legislation or regulation would not have a material adverse effect on the Company’s financial position, results of operations, or cash flows. In a number of states targeted flavor bans have been proposed or enacted legislatively or by the administrative process. Depending on the number and location of such bans, that legislation or regulation could have a material adverse effect on the Company’s financial position, results of operations or cash flows. Food and Drug Administration (“FDA”) continues to consider various restrictive regulations around our products, including targeted flavor bans; however, the details, timing, and ultimate implementation of such measures remain unclear.
The tobacco industry has experienced, and is experiencing, significant product liability litigation. Most tobacco liability lawsuits have been brought against manufacturers and sellers of cigarettes for injuries allegedly caused by smoking or exposure to smoke. However, several lawsuits have been brought against manufacturers and sellers of smokeless products for injuries to health allegedly caused by use of smokeless products. Typically, such claims assert that use of smokeless products is addictive and causes oral cancer. Additionally, several lawsuits have been brought against manufacturers and distributors of NewGen products due to malfunctioning devices. There can be no assurance the Company will not sustain losses in connection with such lawsuits and that such losses will not have a material adverse effect on the Company’s financial position, results of operations, or cash flows.
Master Settlement Agreement (MSA): Pursuant to the Master Settlement Agreement (the “MSA”) entered into in November 1998 by most states (represented by their attorneys general acting through the National Association of Attorneys General) and subsequent states’ statutes, a “cigarette manufacturer” (which is defined to include a manufacturer of make-your-own (“MYO”) cigarette tobacco) has the option of either becoming a signatory to the MSA or opening, funding, and maintaining an escrow account to have funds available for certain potential tobacco-related liabilities with sub-accounts on behalf of each settling state. Such companies are entitled to direct the investment of the escrowed funds and withdraw any appreciation, but cannot withdraw the principal for twenty-five years from the year of each annual deposit, except to withdraw funds deposited pursuant to an individual state’s escrow statute to pay a final judgement to that state’s plaintiffs in the event of such a final judgement against the Company. The Company chose to open and fund an escrow account as its method of compliance. It is the Company’s policy to record amounts on deposit in the escrow account for prior years as a non-current asset. Each year’s annual obligation is required to be deposited in the escrow account by April 15 of the following year. In addition to the annual deposit, many states have elected to require quarterly deposits for the previous quarter’s sales. As of September 30, 2020, the Company had on deposit approximately $32.1 million, the fair value of which was approximately $32.1 million. At December 31, 2019, the Company had on deposit approximately $32.1 million, the fair value of which was approximately $32.1 million. Effective in the third quarter of 2017, the Company no longer sells any product covered under the MSA. Thus, absent a change in legislation, the Company will no longer be required to make deposits to the MSA escrow account.
The Company has chosen to invest a portion of the MSA escrow, from time to time, in U.S. Government securities including TIPS, Treasury Notes, and Treasury Bonds. These investments are classified as available-for-sale and carried at fair value. Realized losses are prohibited under the MSA; any investment in an unrealized loss position will be held until the value is recovered, or until maturity. All monies at September 30, 2020 and December 31, 2019 were held in money market savings accounts.
The following shows the amount of deposits by sales year for the MSA escrow account:
Food and Drug Administration: On June 22, 2009, the Family Smoking Prevention and Tobacco Control Act (the “TCA”) authorized the FDA to immediately regulate the manufacturing, sale, and marketing of four categories of tobacco products – cigarettes, cigarette tobacco, roll-your-own tobacco, and smokeless tobacco.
Under the TCA, tobacco product user fees are assessed on six classes of regulated tobacco products. The user fees are computed using a methodology similar to the methodology used by the U.S Department of Agriculture to compute the Tobacco Transition Payment Program assessment. First, the total, annual, congressionally established user fee assessment is allocated among the various classes of tobacco products using the federal excise tax weighted market share of tobacco products subject to regulation. Then, the assessment for each class of tobacco products is divided among individual manufacturers and importers.
In August 2016, the FDA’s regulatory authority under the TCA was extended to all tobacco products not previously covered, including: (i) certain NewGen products (such as electronic cigarettes, vaporizers and e-liquids) and their components or parts (such as tanks, coils and batteries); (ii) cigars and their components or parts (such as cigar tobacco); (iii) pipe tobacco; (iv) hookah products; and (v) any other tobacco product “newly deemed” by the FDA. These “deeming regulations” apply to all products made or derived from tobacco intended for human consumption, but excluding accessories of tobacco products (such as lighters). Accordingly, the FDA has since regulated our cigar and cigar wrap products as well as our vapor products containing tobacco-derived nicotine and products intended or reasonably expected to be used to consume such e-liquids.
Under the deeming regulations, the FDA has responsibility for conducting premarket review of “new tobacco products”—defined as those products not commercially marketed in the United States as of February 15, 2007. There are three pathways for obtaining premarket authorization, including submission of a premarket tobacco product application (“PMTA”).
When the FDA initially issued the deeming regulations, it recognized that many products in the deemed categories that were already on the market qualified as “new tobacco products” and lacked a marketing order. In August 2017, the FDA issued a compliance policy (the “August 2017 Guidance”) that allowed new tobacco products to remain on the market without an FDA authorization until specified deadlines had passed. Under the August 2017 Guidance, compliance dates vary depending upon the type of application submitted, but all newly-deemed products require an application no later than August 8, 2021, for “combustible” products (e.g. cigar and pipe), and August 8, 2022, for “non-combustible” products (e.g. vapor products) with the exception of “grandfathered” products (products in commerce as of February 15, 2007) which are already authorized.
On March 27, 2018, several public health organizations filed a lawsuit (the “Maryland Lawsuit”) challenging the August 2017 Guidance. The plaintiffs asserted, among other arguments, that the modification to the deeming regulations included in the August 2017 Guidance conflicts with the TCA and exceeds FDA’s statutory authority.
The court found in favor of the plaintiffs in May 2019 and vacated the August 2017 Guidance. On July 12, 2019, the court issued its remedy order (the “Remedy Order”). Specifically, the court ordered that: (1) for all deemed new tobacco products, marketers must file applications within 10 months of the Remedy Order to continue marketing such products; (2) such a product may remain on the market pending FDA review of a timely filed application for a period not to exceed one year from the date of the application’s submission; (3) in its discretion, the FDA may enforce the premarket review requirements against such products for which marketers do not file applications within 10 months; and (4) the FDA will have the ability to exempt deemed new tobacco products from these application submission requirements for good cause, on a case-by-case basis. FDA appealed the Remedy Order and other actions adverse to the FDA; however, on May 4, 2020, the U.S. Court of Appeals for the Fourth Circuit issued a ruling dismissing the appeals in their entirety.
On March 30, 2020, citing the impacts of the worldwide COVID-19 pandemic on both FDA and industry, FDA requested a modification to the Remedy Order that would extend the May 12, 2020, deadline for filing premarket applications by 120 days to September 9, 2020. After several procedural steps, the Remedy Order was modified on April 22, 2020, to reflect the new deadline, and since then, FDA has updated relevant Guidance documents to reflect this new timeline.
In January 2020, FDA issued a Guidance document (the “January 2020 Guidance”) that stated it would be prioritizing enforcement of several categories of electronic nicotine delivery systems (“ENDS”) products: (1) flavored, cartridge-based ENDS products (other than tobacco- or menthol-flavored ENDS products); (2) ENDS products for which the manufacturer has failed to take (or is failing to take) adequate measures to prevent minors’ access; (3) ENDS products targeted to minors or whose marketing is likely to promote the use of ENDS by minors; and (4) ENDS products offered for sale after the May 12, 2020, premarket application deadline for which the manufacturer has not submitted a premarket application. The policy outlined several factors the agency would consider in its enforcement of flavored cigars going forward but did not drastically restrict those products as it had considered in its March 2019 Guidance proposal. The FDA’s policy on these and other regulated products may change or expand over time in ways not yet known and may significantly impact our products or our premarket filings.
We filed premarket filings prior to the September 9, 2020, deadline for certain of our products and intend to supplement and complete the applications within FDA’s discretionary timeline. A successful PMTA must demonstrate that the subject product is “appropriate for the protection of public health,” taking into account the effect of the marketing of the product on all sub-populations while a Substantial Equivalence Report must demonstrate that a new product either has the same characteristics as its predicate product or different characteristics, but does not raise different questions of public health. FDA has issued a number of proposed rules related to premarket filings; however, none of these rules are final yet, and their requirements may shift before being finalized. We believe we have products that meet the requisite standards and have filed premarket filings supporting a showing of the respective required standard. However, there is no assurance that the FDA’s guidance or ultimate regulation will not change, the Remedy Order will not be further altered or that unforeseen circumstances will not arise that prevent us from sufficiently supplementing or completing our applications or otherwise increase the amount of time and money we are required to spend to receive all necessary marketing orders. Although we filed many premarket applications in a timely manner, no assurance can be given that the applications will ultimately be successful. This may result in the prioritization of supplementing or completing applications for high priority SKUs in our inventory position, which could adversely impact future revenues.
In addition, we currently distribute many third-party manufactured vapor products for which we will be completely dependent on the manufacturer complying with the premarket filing requirements. There can be no assurance that these third-party products will receive a marketing order. While we will take measures to pursue regulatory compliance for our own privately-branded or proprietary vape products that compete with these third-party products, there is no assurance that such proprietary products would be as successful in the marketplace or can fully displace third-party products that are currently being distributed by us, which could adversely affect our results of operations and liquidity. For a period of time after the filing deadline, we expect there to be a lack of enforcement, which may adversely affect our ability to compete in the marketplace against those who continue to sell unauthorized products.
Recent Accounting Pronouncements Adopted
In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 is intended to improve financial reporting by requiring timelier recording of credit losses on loans and other financial instruments held by financial institutions and other organizations. This ASU applies to financial assets measured at amortized cost, including loans, held-to-maturity debt securities, net investments in leases, and trade accounts receivable as well as certain off-balance sheet credit exposures, such as loan commitments. The ASU replaced the previous incurred loss impairment methodology with a methodology to reflect current expected credit losses (“CECL”) and requires consideration of a broader range of reasonable and supportable information to explain credit loss estimates. The guidance was adopted using a modified retrospective transition method through a cumulative-effect adjustment to retained earnings/(deficit) in the period of adoption. The ASU was effective for the Company beginning in the first quarter of 2020. The ASU did not have an impact to the Company’s financial statements and related disclosures.
In August 2018, the FASB issued ASU 2018-15, Intangibles — Goodwill and Other — Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. ASU 2018-15 aligns the requirements for capitalizing implementation costs in a cloud computing arrangement service contract with the requirements for capitalizing implementation costs incurred for an internal-use software license. The guidance is effective for interim and annual periods beginning after December 15, 2019, with early adoption permitted. The Company adopted ASU 2018-15 effective January 1, 2020. The ASU did not have an impact to the Company’s financial statements and related disclosures.
Recent Accounting Pronouncements Not Yet Adopted
In December 2019, the FASB issued ASU 2019-12 to simplify the accounting in ASC 740, Income Taxes. This guidance removes certain exceptions related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period, and the recognition of deferred tax liabilities for outside basis differences. This guidance also clarifies and simplifies other areas of ASC 740. This ASU will be effective beginning in the first quarter of the Company’s fiscal year 2021. Early adoption is permitted. Certain amendments in this update must be applied on a prospective basis, certain amendments must be applied on a retrospective basis, and certain amendments must be applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings/(deficit) in the period of adoption. The Company is currently evaluating the impact this ASU will have on the financial statements and related disclosures, as well as the timing of adoption.
In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40). This guidance simplifies the accounting for convertible debt instruments by reducing the number of accounting models and the number of embedded conversion features that could be recognized separately from the convertible instrument. This guidance also enhances transparency and improves disclosures for convertible instruments and earnings per share guidance. This ASU is effective for annual reporting periods beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. This update permits the use of either the modified retrospective or fully retrospective method of transition. The Company is currently evaluating the impact this ASU will have on the financial statements and related disclosures, as well as the timing of adoption.
|
Acquisitions |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2020 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Acquisitions [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Acquisitions |
Note 3. Acquisitions
Standard Diversified Inc. (“SDI”) Reorganization
On July 16, 2020, the Company completed its merger with SDI, whereby SDI was merged into a wholly-owned subsidiary of the Company in a tax-free downstream merger. Under the terms of the agreement, the holders of SDI’s Class A Common Stock and SDI’s Class B Common Stock (collectively, “SDI Common Stock”) received in the aggregate, in return for their SDI Common Stock, TPB Voting Common Stock (“TPB Common Stock”) at a ratio of 0.52095 shares of TPB Common Stock for each share of SDI Common Stock at the time of the merger. SDI divested its assets, other than SDI’s TPB Common Stock, prior to close such that the net liabilities at closing were minimal and the only assets that SDI retained were the remaining TPB Common Stock holdings. The transaction was accounted for as an asset purchase for $236.0 million in consideration, comprised of 7,934,704 shares of TPB Common Stock valued at $234.3 million plus transaction costs and assumed net liabilities. $236.0 million was assigned to the 8,178,918 shares of TPB Common Stock acquired. Shares of TPB Common Stock acquired in excess of the shares issued were retired. The Company no longer has a controlling shareholder and 244,214 shares of TPB Common Stock were retired resulting in a charge of $1.7 million recorded in Accumulated earnings (deficit).
Durfort Holdings
In June 2020, the Company purchased certain tobacco assets and distribution rights from Durfort Holdings S.R.L. (“Durfort”) and Blunt Wrap USA for $47.7 million in total consideration, comprised of $37.7 million in cash, including $1.7 million of capitalized transaction costs, and a $10.0 million unsecured subordinated promissory note (“Promissory Note”). With this transaction, the Company acquired co-ownership in the intellectual property rights of all of Durfort’s and Blunt Wrap USA’s Homogenized Tobacco Leaf (“HTL”) cigar wraps and cones. The Company also entered into an exclusive Master Distribution Agreement to market and sell the original Blunt Wrap® cigar wraps within the USA which was effective October 9, 2020. Durfort is an industry leader in alternative cigar and cigar wrap manufacturing and distribution. Blunt Wrap USA has been an innovator of new products in the smoking alternative market since 1997 and has secured patents in the USA and internationally for novel smoking wrappers and cones. The transaction was accounted for as an asset purchase with $42.2 million assigned to intellectual property, which has an indefinite life, and $5.5 million assigned to the Master Distribution Agreement, which has a 15 year life. Both assets are currently deductible for tax purposes.
Solace Technologies
In July 2019, the Company purchased the assets of E-Vape 12, Inc. and Solace Technologies LLC (“Solace”) for $9.4 million in total consideration, comprised of $7.7 million in cash, $1.1 million earn-out fair value, and $0.5 million holdback for 18 months, which was adjusted by $0.2 million for a working capital deficiency. The earn-out consists of 44,295 shares of TPB Common Stock to be issued to the former owners upon the achievement of certain annual milestones. Immediately following the acquisition, 88,582 performance based restricted stock units (“PRSUs”) with a fair value of $4.62 million were issued to former owners who became employees. See Note 15, “Share Incentive Plans”, for further details. Solace is an innovative product development company that has grown from the creator of one of the leading vape juice brands in the industry into a leader of alternative ingredients product development. The Company intends to incorporate Solace’s innovative products as well as the legacy vapor products into our Nu-X development engine. The Company completed the accounting for the acquisition during the third quarter 2020. The following purchase price and goodwill are based on the excess of the acquisition price over the estimated fair value of the tangible and intangible assets acquired:
The goodwill of $6.4 million consists of the synergies and scale expected from combining the operations and is currently deductible for tax purposes.
|
Derivative Instruments |
9 Months Ended |
---|---|
Sep. 30, 2020 | |
Derivative Instruments [Abstract] | |
Derivative Instruments |
Note 4. Derivative Instruments
Foreign Currency
The Company’s policy is to manage the risks associated with foreign exchange rate movements. The policy allows hedging up to 100% of its anticipated purchases of inventory over a forward period that will not exceed 12 rolling and consecutive months. The Company may, from time to time, hedge currency for non-inventory purchases, e.g., production equipment, not to exceed 90% of the purchase price. During the third quarter 2020, the Company executed various forward contracts, which met hedge accounting requirements, for the purchase of €19.7 million and sale of €21.4 million with maturity dates ranging from December 2020 to November 2021. At September 30, 2020, the Company had forward contracts for the purchase of €19.7 million and sale of €21.4 million. The foreign currency contracts’ fair value at September 30, 2020, resulted in an asset of $0.3 million included in Other current assets and a liability of $0.2 million included in Accrued liabilities.
Interest Rate Swaps
The Company’s policy is to manage interest rate risk by reducing the volatility of future cash flows associated with debt instruments bearing interest at variable rates. In March 2018, the Company executed various interest rate swap agreements for a notional amount of $70 million with an expiration of December 2022. The swap agreements fix LIBOR at 2.755%. The swap agreements met the hedge accounting requirements; thus, any change in fair value is recorded to other comprehensive income. The Company uses the Shortcut Method to account for the swap agreements. The Shortcut Method assumes the hedge to be perfectly effective; thus, there is no ineffectiveness to be recorded in earnings. The swap agreements’ fair values at September 30, 2020, and December 31, 2019, resulted in a liability of $4.2 million and $2.5 million, respectively, included in other long-term liabilities. Losses of $0.5 million and $1.0 million were reclassified into interest expense for the three and nine months ended September 30, 2020, respectively. Losses of $0.1 million and $0.2 million were reclassified into interest expense for the three and nine months ended September 30, 2019, respectively.
|
Fair Value of Financial Instruments |
9 Months Ended |
---|---|
Sep. 30, 2020 | |
Fair Value of Financial Instruments [Abstract] | |
Fair Value of Financial Instruments |
Note 5. Fair Value of Financial Instruments
The estimated fair value amounts have been determined by the Company using the methods and assumptions described below. However, considerable judgment is required to interpret market data to develop estimates of fair value. Accordingly, the estimates presented herein are not necessarily indicative of the amounts the Company could realize in a current market exchange. The use of different market assumptions and/or estimation methodologies may have a material effect on the estimated fair value amounts.
Cash and Cash Equivalents
Cash and cash equivalents are, by definition, short-term. Thus, the carrying amount is a reasonable estimate of fair value.
Accounts Receivable
The fair value of accounts receivable approximates their carrying value due to their short-term nature.
Long-Term Debt
The Company’s 2018 Credit Facility bears interest at variable rates that fluctuate with market rates, the carrying values of the long-term debt instruments approximate their respective fair values. As of September 30, 2020, the fair value of the 2018 First Lien Term Loan approximated $138.0 million. As of December 31, 2019, the fair value of the 2018 First Lien Term Loan approximated $146.0 million.
The Convertible Senior Notes bear interest at a rate of 2.50% per year and the fair value approximated $144.7 million, with a carrying value of $172.5 million as of September 30, 2020. As of December 31, 2019, the fair value of the Convertible Senior Notes approximated $140.1 million, with a carrying value of $172.5 million.
Note Payable – Promissory Note
The fair value of the Promissory Note approximates its carrying value of $10.0 million due to the recency of the note’s issuance, related to the quarter ended September 30, 2020.
Note Payable – Unsecured Loan
The fair value of the Unsecured Note approximates its carrying value of $7.5 million due to the recency of the note’s issuance, related to the quarter ended September 30, 2020.
See Note 11, “Notes Payable and Long-Term Debt”, for further information regarding the Company’s long-term debt.
Foreign Exchange
At September 30, 2020, the Company had forward contracts for the purchase of €19.7 million and sale of €21.4 million. The fair value of the foreign exchange contracts are based upon quoted market prices for similar instruments, thus leading to a level 2 distinction within the fair value hierarchy, and resulted in an asset of $0.3 million and a liability of $0.2 million as of September 30, 2020.
Interest Rate Swaps
The Company had swap contracts for a total notional amount of $70 million at September 30, 2020 and December 31, 2019. The fair values of the swap contracts are based upon quoted market prices for similar instruments, thus leading to a level 2 distinction within the fair value hierarchy, and resulted in a liability of $4.2 million and $2.5 million as of September 30, 2020 and December 31, 2019, respectively.
|
Inventories |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2020 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventories [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventories |
Note 6. Inventories
The components of inventories are as follows:
The inventory valuation allowance was $13.4 million and $21.5 million as of September 30, 2020, and December 31, 2019, respectively. Inventory reserves increased in the fourth quarter 2019 as a result of additional reserves necessary for products in our NewGen segment primarily from increased regulation.
|
Other Current Assets |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2020 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other Current Assets [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other Current Assets |
Note 7. Other Current Assets
Other current assets consist of:
|
Property, Plant, and Equipment |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2020 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Property, Plant, and Equipment [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Property, Plant and Equipment |
Note 8. Property, Plant, and Equipment
Property, plant, and equipment consists of:
|
Other Assets |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2020 | ||||||||||||||||||||||||||||||||||||||||||||||
Other Assets [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||
Other Assets |
Note 9. Other Assets
Other assets consist of:
|
Accrued Liabilities |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2020 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued Liabilities [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued Liabilities |
Note 10. Accrued Liabilities
Accrued liabilities consist of:
|
Notes Payable and Long-Term Debt |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2020 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes Payable and Long-Term Debt [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes Payable and Long-Term Debt |
Note 11. Notes Payable and Long-Term Debt
Notes payable and long-term debt consists of the following in order of preference:
2018 Credit Facility
On March 7, 2018, the Company entered into $250 million of credit facilities consisting of a $160 million 2018 First Lien Term Loan and a $50 million 2018 Revolving Credit Facility (collectively, the “2018 First Lien Credit Facility”), in each case, with Fifth Third Bank, as administrative agent, and other lenders, in addition to a $40 million 2018 Second Lien Term Loan (the “2018 Second Lien Credit Facility,” and, together with the 2018 First Lien Credit Facility, the “2018 Credit Facility”) with Prospect Capital Corporation, as administrative agent, and other lenders. The 2018 Credit Facility contains a $40 million accordion feature.
The 2018 Credit Facility contains customary events of default including payment defaults, breaches of representations and warranties, covenant defaults, cross-defaults to certain other material indebtedness in excess of specified amounts, certain events of bankruptcy and insolvency, certain ERISA events, judgments in excess of specified amounts, and change in control defaults. The 2018 Credit Facility also contains certain negative covenants customary for facilities of these types including covenants that, subject to exceptions described in the 2018 Credit Facility, restrict the ability of the Company and its subsidiary guarantors: (i) to pledge assets, (ii) to incur additional indebtedness, (iii) to pay dividends, (iv) to make distributions, (v) to sell assets, and (vi) to make investments. See Note 19, “Dividends and Share Repurchase”, for further information regarding dividend restrictions.
2018 First Lien Credit Facility: The 2018 First Lien Term Loan and the 2018 Revolving Credit Facility bear interest at LIBOR plus a spread of 2.75% to 3.50% based on the Company’s senior leverage ratio. The 2018 First Lien Term Loan has quarterly required payments of $2.0 million beginning June 30, 2018, increasing to $3.0 million on June 30, 2020, and increasing to $4.0 million on June 30, 2022. The 2018 First Lien Credit Facility has a maturity date of March 7, 2023. The 2018 First Lien Term Loan is secured by a first priority lien on substantially all of the assets of the borrowers and the guarantors thereunder, including a pledge of the Company’s capital stock, other than certain excluded assets (the “Collateral”). In connection with the Convertible Senior Notes offering, the Company entered into a First Amendment (“the Amendment”) to the First Lien Credit Agreement, with Fifth Third Bank, as administrative agent, and other lenders and certain other lender parties thereto. The Amendment was entered into primarily to permit the Company to issue up to $200 million of convertible senior notes, enter into certain capped call transactions in connection with the issuance of such notes and to use the proceeds from the issuance of the notes to repay amounts outstanding under the 2018 Second Lien Credit Facility and use the remaining proceeds for acquisitions and investments. In connection with the Amendment, fees of $0.7 million were incurred. The 2018 First Lien Credit Facility contains certain financial covenants, which were amended in connection with the Convertible Senior Notes offering in the third quarter 2019. The covenants include maximum senior leverage ratio of 3.00x with step-downs to 2.50x, a maximum total leverage ratio of 5.50x with step-downs to 5.00x, and a minimum fixed charge coverage ratio of 1.20x. In the first quarter of 2020, the financial covenants were amended to permit certain add-backs related to PMTA in the definition of Consolidated EBITDA for the period of October 1, 2019 until September 30, 2020. In connection with the amendment, fees of $0.2 million were incurred. Based on an excess cash covenant for the facility, a principal payment of $4.5 million was due in the second quarter 2019. All parties agreed to waive the payment, resulting in consent fees of $0.1 million. The weighted average interest rate of the 2018 First Lien Term Loan was 2.91% at September 30, 2020. At September 30, 2020, the Company had no borrowings outstanding under the 2018 Revolving Credit Facility. The $50.0 million unused portion of the 2018 Revolving Credit Facility is reduced by letters of credit issued by Fifth Third Bank totaling $3.6 million, resulting in $46.4 million of availability under the 2018 Revolving Credit Facility at September 30, 2020.
2018 Second Lien Credit Facility: The 2018 Second Lien Credit Facility bore interest at a rate of LIBOR plus 7.00% and had a maturity date of March 7, 2024. The 2018 Second Lien Term Loan was secured by a second priority interest in the Collateral and was guaranteed by the same entities as the 2018 First Lien Term Loan. Based on an excess cash covenant for the facility, a $4.5 million principal payment was made in the second quarter 2019, resulting in a $0.2 million loss on extinguishment of debt. The Company used a portion of the proceeds from the issuance of the Convertible Senior Notes to prepay all outstanding amounts related to the 2018 Second Lien Credit Facility in the third quarter 2019 in the amount of $35.5 million, and the transaction resulted in a $1.1 million loss on extinguishment of debt.
Convertible Senior Notes
In July 2019, the Company closed an offering of $172.5 million in aggregate principal amount of its 2.50% Convertible Senior Notes due July 15, 2024 (the “Convertible Senior Notes”). The Convertible Senior Notes bear interest at a rate of 2.50% per year, payable semiannually in arrears on January 15 and July 15 of each year, beginning on January 15, 2020. The Convertible Senior Notes will mature on July 15, 2024, unless earlier repurchased, redeemed or converted. The Convertible Senior Notes are senior unsecured obligations of the Company.
The Convertible Senior Notes are convertible into approximately 3,202,808 shares of TPB Common Stock under certain circumstances prior to maturity at a conversion rate of 18.567 shares per $1,000 principal amount of the Convertible Senior Notes, which represents a conversion price of approximately $53.86 per share, subject to adjustment under certain conditions, but will not be adjusted for any accrued and unpaid interest. Upon conversion, the Company may pay cash, shares of common stock or a combination of cash and stock, as determined by the Company at its discretion. The conditions required to allow the holders to convert their Convertible Senior Notes were not met as of September 30, 2020.
Under GAAP, certain convertible debt instruments that may be settled in cash on conversion are required to be separately accounted for as liability and equity components of the instrument in a manner that reflects the issuer’s non-convertible debt borrowing rate. Accordingly, in accounting for the issuance of the Convertible Senior Notes, the Company separated the Convertible Senior Notes into liability and equity components. The carrying amount of the liability component was calculated by measuring the fair value of a similar liability that does not have an associated convertible feature. The carrying amount of the equity component, which is recognized as a debt discount, represents the difference between the proceeds from the issuance of the Convertible Senior Notes and the fair value of the liability component of the Convertible Senior Notes. The excess of the principal amount of the liability component over its carrying amount (“debt discount”), $35.0 million, will be amortized to interest expense using an effective interest rate of 7.5% over the expected life of the Convertible Senior Notes. The equity component is not remeasured as long as it continues to meet the criteria for equity classification. Interest expense includes $1.8 million and $5.3 million of amortization for the three and nine months, respectively, ended September 30, 2020.
In accounting for the issuance costs related to the issuance of the Convertible Senior Notes, the Company allocated the total amount incurred to the liability and equity components based on their relative fair values. Debt issuance costs attributable to the liability component are amortized to interest expense using the effective interest method over the expected life of the Convertible Senior Notes, $4.7 million, and the debt issuance costs attributable to the equity component, $1.2 million, are netted with the equity component of stockholders’ equity (deficit).
In connection with the Convertible Senior Notes offering, the Company entered into privately negotiated capped call transactions with certain financial institutions. The capped call transactions have a strike price of $53.86 per and a cap price of $82.86 per, and are exercisable when, and if, the Convertible Senior Notes are converted. The Company paid $20.53 million for these capped calls and charged that amount to additional paid-in capital.
Promissory Note
On June 10, 2020, in connection with the acquisition of certain Durfort assets, the Company issued the Promissory Note in the principal amount of $10.0 million (the “Principal Amount”), with an annual interest rate of 7.5%, payable quarterly, with the first payment due September 10, 2020. The Principal Amount is payable in two $5.0 million installments, with the first installment due 18 months after the closing date of the acquisition (June 10, 2020), and the second installment due 36 months after the closing date of the acquisition. The second installment is subject to reduction for certain amounts payable to the Company as a holdback.
Unsecured Loan
On April 6, 2020, the 2018 First Lien Credit Facility was amended to allow for an unsecured loan under the Coronavirus Aid, Relief, and Economic Security Act of 2020 (“CARES”). On April 17, 2020, National Tobacco Company, L.P., a subsidiary of the Company, entered into a loan agreement with Regions Bank guaranteed by the Small Business Administration for a $7.5 million unsecured loan. The proceeds of the loan were received on April 27, 2020. The loan is scheduled to mature on April 17, 2022 and has a 1.00% interest rate.
Note Payable – IVG
In September 2018, the Company issued a note payable to IVG’s former shareholders (“IVG Note”). The IVG Note had a principal amount of $4.0 million with 6.0% interest compounding annually and matured on March 5, 2020. All principal and accrued and unpaid interest under the IVG Note were subject to indemnification obligations of the sellers pursuant to the International Vapor Group Stock Purchase Agreement dated as of September 5, 2018. The carrying amount of the IVG Note, $4.2 million, was deposited into an escrow account pending agreement with the sellers of any indemnification obligations.
|
Leases |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2020 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Leases [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Leases |
Note 12. Leases
As of January 1, 2019, the Company adopted ASU 2016-02, Leases (Topic 842). The main impact to the financial statements is the recognition of lease liabilities and right of use assets. The Company’s leases consist primarily of leased property for manufacturing warehouse, head offices and retail space as well as vehicle leases. In general, the Company does not recognize any renewal periods within the lease terms as there are not significant barriers to ending the lease at the initial term. Lease and non-lease components are accounted for as a single lease component.
Leases with an initial term of 12 months or less are not recorded on the balance sheet. Lease expense for these leases is recognized on a straight-line basis over the lease term.
The components of lease expense consisted of the following:
Nearly all the lease contracts for the Company do not provide a readily determinable implicit rate. For these contracts, the Company estimated the incremental borrowing rate based on information available upon adoption of ASU 2016-02. The Company applied a consistent method in periods after the adoption of ASU 2016-02 to estimate the incremental borrowing rate.
As of September 30, 2020, and December 31, 2019, maturities of lease liabilities consisted of the following:
During the third quarter of the year, the Company entered into one new lease agreement which resulted in an increase in lease liability of $6.6 million as of September 30, 2020.
|
Income Taxes |
9 Months Ended |
---|---|
Sep. 30, 2020 | |
Income Taxes [Abstract] | |
Income Taxes |
Note 13. Income Taxes
The Company’s effective income tax rate for the three and nine months ended September 30, 2020, was 18.9% and 22.9%, respectively, which includes a discrete tax deduction of $0.0 million and $0.9 million for the three and nine months ended September 30, 2020, respectively, relating to stock option exercises, and a discrete tax benefit of $0.6 million for the three and nine months ended, September 30, 2020, relating to the valuation release in other comprehensive income from the defined benefit pension plan. The Company’s effective income tax rate for the three and nine months ended September 30, 2019, was 26.3% and 21.2%, respectively, which includes a discrete tax deduction of $0.1 million and $4.6 million for the three and nine months ended September 30, 2019, respectively, relating to stock option exercises.
The Company follows the provisions of ASC 740-10-25, which prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. The amount recognized is measured as the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. The Company has determined that the Company did not have any uncertain tax positions requiring recognition under the provisions of ASC 740-10-25. The Company’s policy is to recognize interest and penalties accrued on uncertain tax positions, if any, as part of interest expense. The Company files income tax returns in the U.S. federal jurisdiction and various state jurisdictions. In general, the Company is no longer subject to U.S. federal and state tax examinations for years prior to 2017.
|
Pension and Postretirement Benefit Plans |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2020 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pension and Postretirement Benefit Plans [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pension and Postretirement Benefit Plans |
Note 14. Pension and Postretirement Benefit Plans
The Company has a defined benefit pension plan. Benefits for hourly employees were based on a stated benefit per year of service, reduced by amounts earned in a previous plan. Benefits for salaried employees were based on years of service and the employees’ final compensation. The defined benefit pension plan was frozen. The Company’s policy is to make the minimum amount of contributions that can be deducted for federal income taxes. The Company expects to make no contributions to the pension plan in 2020. In October 2019, the Company elected to terminate the defined benefit pension plan, effective December 31, 2019 with final distributions made in third quarter of 2020.
The Company sponsored a defined benefit postretirement plan that covered hourly employees. This plan provides medical and dental benefits. This plan was contributory with retiree contributions adjusted annually. The Company’s policy was to make contributions equal to benefits paid during the year. The Company does not expect to contribute to its postretirement plan in 2020 for the payment of benefits. In October 2019, the Company amended the plan to cease benefits effective June 30, 2020.
The following table provides the components of net periodic pension and postretirement benefit costs and total costs for the plans:
|
Share Incentive Plans |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2020 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share Incentive Plans [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share Incentive Plans |
Note 15. Share Incentive Plans
On April 28, 2016, the Board of Directors of the Company adopted the Turning Point Brands, Inc., 2015 Equity Incentive Plan (the “2015 Plan”), pursuant to which awards may be granted to employees, non-employee directors, and consultants. In addition, the 2015 Plan provides for the granting of nonqualified stock options to employees of the Company or any subsidiary of the Company. Pursuant to the 2015 Plan, 1,400,000 shares of TPB Common Stock are reserved for issuance as awards to employees, non-employee directors, and consultants as compensation for past or future services or the attainment of certain performance goals. The 2015 Plan is scheduled to terminate on April 27, 2026. The 2015 Plan is administered by a committee (the “Committee”) of the Company’s Board of Directors. The Committee determines the vesting criteria for the awards, with such criteria to be specified in the award agreement. As of September 30, 2020, net of forfeitures, there were 16,159 shares of restricted stock, 440,132 PRSUs, and 610,730 options granted under the 2015 Plan. There are 332,979 shares available for grant under the 2015 Plan.
On February 8, 2006, the Board of Directors of the Company adopted the 2006 Equity Incentive Plan (the “2006 Plan”) of North Atlantic Holding Company, Inc., pursuant to which awards may be granted to employees. The 2006 Plan provides for the granting of nonqualified stock options and restricted stock awards to employees. Upon the adoption of the Company’s 2015 Equity Incentive Plan in connection with its IPO, the Company determined no additional grants would be made under the 2006 Plan. However, all awards issued under the 2006 Plan that have not been previously terminated or forfeited remain outstanding and continue unaffected.
There are no shares available for grant under the 2006 Plan. Stock option activity for the 2006 and 2015 Plans is summarized below:
Under the 2006 and 2015 Plans, the total intrinsic value of options exercised during the nine months ended September 30, 2020 and 2019, was $0.9 million, and $4.6 million, respectively.
At September 30, 2020, under the 2006 Plan, the outstanding stock options’ exercise price for 272,681 options is $3.83 per share, all of which are exercisable. The weighted average of the remaining lives of the outstanding stock options with an exercise price of $3.83 is approximately 2.95 years. The Company estimates the expected life of these stock options is ten years from the date of grant. For the $3.83 per share options, the weighted average fair value of options was determined using the Black-Scholes model assuming a ten-year life from grant date, a current share price and exercise price of $3.83, a risk-free interest rate of 3.57%, volatility of 40%, and no assumed dividend yield. Based on these assumptions, the fair value of these options is approximately $2.17 per share option granted.
At September 30, 2020, under the 2015 Plan, the risk-free interest rate is based on the U.S. Treasury rate for the expected life at the time of grant. The expected volatility is based on the average long-term historical volatilities of peer companies. We intend to continue to consistently use the same group of publicly traded peer companies to determine expected volatility until sufficient information regarding volatility of our share price becomes available or until the selected companies are no longer suitable for this purpose. Due to our limited trading history, we are using the simplified method presented by SEC Staff Accounting Bulletin No. 107 to calculate expected holding periods, which represent the periods of time for which options granted are expected to be outstanding. We will continue to use this method until we have sufficient historical exercise experience to give us confidence in the reliability of our calculations. The fair values of these options were determined using the Black-Scholes option pricing model.
The following table outlines the assumptions based on the number of options granted under the 2015 Plan.
The Company has recorded compensation expense related to the options based on the provisions of ASC 718 under which the fixed portion of such expense is determined as the fair value of the options on the date of grant and amortized over the vesting period. The Company recorded compensation expense related to the options of approximately $0.3 million and $0.5 million for the three months ended September 30, 2020 and 2019, respectively. The Company recorded compensation expense related to the options of approximately $0.9 million and $1.2 million for the nine months ended September 30, 2020 and 2019, respectively. Total unrecognized compensation expense related to options at September 30, 2020, is $0.9 million, which will be expensed over 1.68 years.
Performance-Based Restricted Stock Units
PRSUs are restricted stock units subject to both performance-based and service-based vesting conditions. The number of shares of TPB Common Stock a recipient will receive upon vesting of a PRSU will be calculated by reference to certain performance metrics related to the Company’s performance over a five-year period. PRSUs will vest on the measurement date, which is no more than 65 days after the performance period provided the applicable service and performance conditions are satisfied. As of September 30, 2020, there are 440,132 PRSUs outstanding, all of which are unvested. The following table outlines the PRSUs granted and outstanding as of September 30, 2020.
The Company recorded compensation expense related to the PRSUs of approximately $0.4 million and $0.6 million in the consolidated statements of income for the three months ended September 30, 2020 and 2019, respectively, based on the probability of achieving the performance condition. The Company recorded compensation expense related to the PRSUs of approximately $1.1 million and $1.3 million in the consolidated statements of income for the nine months ended September 30, 2020 and 2019, respectively, based on the probability of achieving the performance condition. Total unrecognized compensation expense related to these awards at September 30, 2020, is $9.4 million which will be expensed over the service periods based on the probability of achieving the performance condition.
|
Contingencies |
9 Months Ended |
---|---|
Sep. 30, 2020 | |
Contingencies [Abstract] | |
Contingencies |
Note 16. Contingencies
On October 9, 2020, a purported stockholder of Turning Point Brands, Inc., Paul-Emile Berteau, filed a complaint in the Delaware Court of Chancery relating to the Agreement and Plan of Merger and Reorganization, dated as of April 7, 2020, by and among TPB, SDI and Merger Sub (the “SDI Merger”). The complaint asserts two derivative counts purportedly on behalf of TPB for breaches of fiduciary duty against the Board of Directors of Turning Point Brands, Inc. and other parties. The third count asserts a direct claim against the Company and its Board of Directors seeking a declaration that TPB’s Bylaws are inconsistent with TPB’s certificate of incorporation. While the Company believes it has good and valid defenses to the claims, there can be no assurance that the Company will prevail in this case, and it could have a material adverse effect on the Company’s business and results of operations.
Other major tobacco companies are defendants in product liability claims. In a number of these cases, the amounts of punitive and compensatory damages sought are significant and could have a material adverse effect on our business and results of operations.
The Company is subject to several lawsuits alleging personal injuries resulting from malfunctioning vaporizer devices or consumption of e-liquids and may be subject to claims in the future relating to other NewGen products. The Company is still evaluating these claims and the potential defenses to them. For example, the Company did not design or manufacture the products at issue; rather, the Company was merely the distributor. Nonetheless, there can be no assurance that the Company will prevail in these cases, and they could have a material adverse effect on the financial position, results of operations, or cash flows of the Company.
Franchisors are defendants from time to time in the ordinary course of business. In certain of these cases, the amounts of punitive and compensatory damages sought are significant. One of the Company’s subsidiaries is a defendant in a lawsuit brought by a franchisee. In that case, the franchisee is seeking compensatory and punitive damages and rescission of their franchise agreement, alleging that the Company’s subsidiary failed to make certain disclosures in the Franchise Disclosure Document. The subsidiary is evaluating these claims, the potential defenses to them as well as available counterclaims. The subsidiary believes that termination of the franchise agreement was proper, no damages are due and the franchisee is bound by an arbitration agreement pursuant to the terms of their franchise agreement (and therefore it was improper to pursue litigation). The former franchisee has also named various other parties, including the Company and another subsidiary asserting the same claims, as well as a claim for a declaratory judgment, that the Company and the subsidiary should be found liable as successor entities, or under the doctrines of “de facto merger”, or alter ego. The Company and the subsidiary have moved to stay the case pending the arbitration noted above. Both motions remain pending. While the Company and its subsidiaries believe they have good and valid defenses to the claims, there can be no assurance that the Company and its subsidiaries will prevail in this case, and it could have a material adverse effect on the Company’s business and results of operations.
The Company has several subsidiaries engaged in making, distributing, and selling vapor products. As a result of the overall publicity and controversy surrounding the vapor industry generally, many companies have received informational subpoenas from various regulatory bodies and in some jurisdictions regulatory lawsuits have been filed regarding marketing practices and possible underage sales. The Company has subsidiaries that are subject to some information requests. In the acquisition of the vapor businesses, the Company negotiated financial “hold-backs”, which it expects to be able to use to defray expenses associated with the information production and the cost of defending any such lawsuits as well as the franchisee lawsuit. To the extent that litigation becomes necessary, the Company believes that the subsidiaries have strong factual and legal defenses against claims that it unfairly marketed vapor products.
|
Income Per Share |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2020 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Income Per Share [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Income Per Share |
Note 17. Income Per Share
The following is a reconciliation of the numerators and denominators of the basic and diluted EPS computations of net income:
For the three and nine months ended September 30, 2020, the effect of the 3,202,808 shares issuable upon conversion of the Convertible Senior Notes were excluded from the diluted net income per share calculation because the Company’s average stock price did not exceed $53.86 during those periods.
|
Segment Information |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2020 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment Information [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment Information |
Note 18. Segment Information
In accordance with ASC 280, Segment Reporting, the Company has three reportable segments: Smokeless products, Smoking products, and NewGen products. The Smokeless products segment (i) manufactures and markets moist snuff and (ii) contracts for and markets loose leaf chewing tobacco products. The Smoking products segment (i) markets and distributes cigarette papers, tubes, and related products; and (ii) contracts for, markets and distributes finished cigars and MYO cigar wraps. The NewGen products segment (i) markets and distributes CBD, liquid vapor products and certain other products without tobacco and/or nicotine; (ii) distributes a wide assortment of products to non-traditional retail via VaporBeast; and (iii) markets and distributes a wide assortment of products to individual consumers via the VaporFi B2C online platform. Smokeless and Smoking products are distributed primarily through wholesale distributors in the United States while NewGen products are distributed primarily through e-commerce to non-traditional retail outlets and direct to consumers in the United States. The Other segment includes the costs and assets of the Company not assigned to one of the three reportable segments such as intercompany transfers, deferred taxes, deferred financing fees, and investments in subsidiaries.
The accounting policies of these segments are the same as those of the Company. Corporate costs are not directly charged to the three reportable segments in the ordinary course of operations. The Company evaluates the performance of its segments and allocates resources to them based on operating income.
The tables below present financial information about reported segments:
Revenue Disaggregation—Sales Channel
Revenues of the Smokeless and Smoking segments are primarily comprised of sales made to wholesalers while NewGen sales are made business to business and business to consumer, both online and through our corporate retail stores. NewGen net sales are broken out by sales channel below.
Net Sales—Domestic vs. Foreign
The following table shows a breakdown of consolidated net sales between domestic and foreign customers.
|
Dividends and Share Repurchase |
9 Months Ended |
---|---|
Sep. 30, 2020 | |
Dividends and Share Repurchase [Abstract] | |
Dividends and Share Repurchase |
Note 19. Dividends and Share Repurchase
The most recent dividend of $0.05 per common share was paid on October 9, 2020, to shareholders of record at the close of business on September 18, 2020.
Dividends are classified as restricted payments within the 2018 Credit Facility. The Company is generally permitted to make restricted payments provided that, at the time of payment, or as a result of payment, the Company is not in default on its debt covenants. Additional restrictions limit the aggregate amount of restricted, quarterly dividends during a fiscal year to the aggregate amount of mandatory and voluntary principal payments made on the priority term loans during the fiscal year.
On February 25, 2020, the Company’s Board of Directors approved a $50.0 million share repurchase authorization, which is intended for opportunistic execution based upon a variety of factors including market dynamics. The authorization is subject to the ongoing discretion of the Board. The total number of shares repurchased for the three months ended September 30, 2020, was 82,097 shares for a total cost of $2.4 million and an average price per share of $28.95. The total number of shares repurchased for the nine months ended September 30, 2020, was 338,960 shares for a total cost of $7.7 million and an average price per share of $22.61.
|
Subsequent Events |
9 Months Ended |
---|---|
Sep. 30, 2020 | |
Subsequent Events [Abstract] | |
Subsequent Events |
Note 20. Subsequent Events
Wild Hempettes LLC
On October 1, 2020, the Company acquired a 20% stake in Wild Hempettes LLC (“Wild Hempettes”), a leading manufacturer of hemp cigarettes under the WildHemp™ and Hempettes™ brands, for $2.5 million. The Company has options to increase its stake to a 100% ownership position based on certain milestones. As part of the transaction, the Wild Hempettes joint venture was spun off from Crown Distributing LLC and formed as a vehicle for the Company to be the exclusive distributor of Hempettes™ to U.S. bricks and mortar retailers under a profit-sharing arrangement. The Company has provided Wild Hempettes with a secured line of credit up to $2.0 million with a term up to 5 years.
Sale of Vapor Shark Retail Assets
On October 1, 2020, the Company sold the assets of its remaining 7 Vapor Shark retail stores in Oklahoma. The Company will receive monthly royalties over the next 4 years as consideration for the assets.
dosistTM
On October 27, 2020, the Company invested $15.0 million in dosistTM, a global cannabinoid company, with an option to invest an additional $15.0 million at pre-determined terms over the next 12 months. The Company will receive a warrant to receive preferred shares of dosist that will automatically be exercised upon the changing of federal laws in the United States, rescheduling cannabis and/or permitting the general cultivation, distribution and possession of cannabis. As part of the investment, the Company also entered into an exclusive co-development and distribution of a new national CBD brand, created in partnership with dosist.
|
Description of Business and Basis of Presentation (Policies) |
9 Months Ended |
---|---|
Sep. 30, 2020 | |
Description of Business and Basis of Presentation [Abstract] | |
Basis of Presentation |
The accompanying unaudited interim, consolidated financial statements have been prepared in accordance with the accounting practices described in the Company’s audited, consolidated financial statements as of and for the year ended December 31, 2019. In the opinion of management, the unaudited, interim, consolidated financial statements included herein contain all adjustments necessary to present fairly the financial position, results of operations, and cash flows of the Company for the periods indicated. Such adjustments, other than nonrecurring adjustments separately disclosed, are of a normal and recurring nature. The operating results for interim periods are not necessarily indicative of results to be expected for a full year or future interim periods. The unaudited, interim, consolidated financial statements should be read in conjunction with the Company’s audited, consolidated financial statements and accompanying notes as of and for the year ended December 31, 2019. The accompanying interim, consolidated financial statements are presented in accordance with the rules and regulations of the Securities and Exchange Commission and, accordingly, do not include all the disclosures required by generally accepted accounting principles in the United States (“GAAP”) with respect to annual financial statements.
|
Reclassifications |
Certain prior year amounts have been reclassified to conform to the current year’s presentation. The changes did not have an impact on the Company’s consolidated financial position, results of operations, or cash flows in any of the periods presented.
|
Summary of Significant Accounting Policies (Policies) |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2020 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of Significant Accounting Policies [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Consolidation |
Consolidation
The consolidated financial statements include the accounts of the Company and its subsidiaries, all of which are wholly-owned. All significant intercompany transactions have been eliminated.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Revenue Recognition |
Revenue Recognition
The Company recognizes revenues in accordance with Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (Topic 606), which includes excise taxes and shipping and handling charges billed to customers, net of cash discounts for prompt payment, sales returns and incentives, upon delivery of goods to the customer – at which time the Company’s performance obligation is satisfied – at an amount that the Company expects to be entitled to in exchange for those goods in accordance with the five-step analysis outlined in Topic 606: (i) identify the contract with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations, and (v) recognize revenue when (or as) performance obligations are satisfied. The Company excludes from the transaction price, sales taxes and value-added taxes imposed at the time of sale (which do not include excise taxes on smokeless tobacco, cigars or vaping products billed to customers).
The Company records an allowance for sales returns, based principally on historical volume and return rates, which is included in accrued liabilities on the consolidated balance sheets. The Company records sales incentives, which consist of consumer incentives and trade promotion activities, as a reduction in revenues (a portion of which is based on amounts estimated as being due to wholesalers, retailers and consumers at the end of the period) based principally on historical volume and utilization rates. Expected payments for sales incentives are included in accrued liabilities on the consolidated balance sheets.
A further requirement of ASU 2014-09 is for entities to disaggregate revenue recognized from contracts with customers into categories that depict how the nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factors. Company management views business performance through segments that closely resemble the performance of major product lines. Thus, the primary and most useful disaggregation of the Company’s contract revenue for decision making purposes is the disaggregation by segment which can be found in Note 18 of Notes to Consolidated Financial Statements. An additional disaggregation of contract revenue by sales channel can be found within Note 18 as well.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shipping Costs |
Shipping Costs
The Company records shipping costs incurred as a component of selling, general, and administrative expenses. Shipping costs incurred were approximately $5.3 million and $4.4 million for the three months ending September 30, 2020 and 2019, respectively. Shipping costs incurred were approximately $17.4 million and $13.6 million for the nine months ending September 30, 2020 and 2019, respectively.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value |
Fair Value
GAAP establishes a framework for measuring fair value. That framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1) and the lowest priority to unobservable inputs (level 3).
The three levels of the fair value hierarchy under GAAP are described below:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative Instruments |
Derivative Instruments
Foreign Currency Forward Contracts: The Company enters into foreign currency forward contracts to hedge a portion of its exposure to changes in foreign currency exchange rates on inventory purchase commitments. The Company accounts for its forward contracts under the provisions of ASC 815, Derivatives and Hedging. Under the Company’s policy, the Company may hedge up to 100% of its anticipated purchases of inventory in the denominated invoice currency over a forward period not to exceed twelve months. The Company may also, from time to time, hedge up to ninety percent of its non-inventory purchases in the denominated invoice currency. Forward contracts that qualify as hedges are adjusted to their fair value through other comprehensive income as determined by market prices on the measurement date, except any hedge ineffectiveness which is recognized currently in income. Gains and losses on these forward contracts are transferred from other comprehensive income into inventory as the related inventories are received and are transferred to net income as inventory is sold. Changes in fair value of any contracts that do not qualify for hedge accounting or are not designated as hedges are recognized currently in income.
Interest Rate Swap Agreements: The Company enters into interest rate swap contracts to manage interest rate risk and reduce the volatility of future cash flows. The Company accounts for its interest rate swap contracts under the provisions of ASC 815, Derivatives and Hedging. Swap contracts that qualify as hedges are adjusted to their fair value through other comprehensive income as determined by market prices on the measurement date, except any hedge ineffectiveness which is recognized currently in income. Gains and losses on these swap contracts are transferred from other comprehensive income into net income upon settlement of the derivative position or at maturity of the interest rate swap contract. Changes in fair value of any contracts that do not qualify for hedge accounting or are not designated as hedges are recognized currently in income.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Risks and Uncertainties |
Risks and Uncertainties
Manufacturers and sellers of tobacco products are subject to regulation at the federal, state, and local levels. Such regulations include, among others, labeling requirements, limitations on advertising, and prohibition of sales to minors. The tobacco industry is likely to continue to be heavily regulated. There can be no assurance as to the ultimate content, timing, or effect of any regulation of tobacco products by any federal, state, or local legislative or regulatory body, nor can there be any assurance that any such legislation or regulation would not have a material adverse effect on the Company’s financial position, results of operations, or cash flows. In a number of states targeted flavor bans have been proposed or enacted legislatively or by the administrative process. Depending on the number and location of such bans, that legislation or regulation could have a material adverse effect on the Company’s financial position, results of operations or cash flows. Food and Drug Administration (“FDA”) continues to consider various restrictive regulations around our products, including targeted flavor bans; however, the details, timing, and ultimate implementation of such measures remain unclear.
The tobacco industry has experienced, and is experiencing, significant product liability litigation. Most tobacco liability lawsuits have been brought against manufacturers and sellers of cigarettes for injuries allegedly caused by smoking or exposure to smoke. However, several lawsuits have been brought against manufacturers and sellers of smokeless products for injuries to health allegedly caused by use of smokeless products. Typically, such claims assert that use of smokeless products is addictive and causes oral cancer. Additionally, several lawsuits have been brought against manufacturers and distributors of NewGen products due to malfunctioning devices. There can be no assurance the Company will not sustain losses in connection with such lawsuits and that such losses will not have a material adverse effect on the Company’s financial position, results of operations, or cash flows.
Master Settlement Agreement (MSA): Pursuant to the Master Settlement Agreement (the “MSA”) entered into in November 1998 by most states (represented by their attorneys general acting through the National Association of Attorneys General) and subsequent states’ statutes, a “cigarette manufacturer” (which is defined to include a manufacturer of make-your-own (“MYO”) cigarette tobacco) has the option of either becoming a signatory to the MSA or opening, funding, and maintaining an escrow account to have funds available for certain potential tobacco-related liabilities with sub-accounts on behalf of each settling state. Such companies are entitled to direct the investment of the escrowed funds and withdraw any appreciation, but cannot withdraw the principal for twenty-five years from the year of each annual deposit, except to withdraw funds deposited pursuant to an individual state’s escrow statute to pay a final judgement to that state’s plaintiffs in the event of such a final judgement against the Company. The Company chose to open and fund an escrow account as its method of compliance. It is the Company’s policy to record amounts on deposit in the escrow account for prior years as a non-current asset. Each year’s annual obligation is required to be deposited in the escrow account by April 15 of the following year. In addition to the annual deposit, many states have elected to require quarterly deposits for the previous quarter’s sales. As of September 30, 2020, the Company had on deposit approximately $32.1 million, the fair value of which was approximately $32.1 million. At December 31, 2019, the Company had on deposit approximately $32.1 million, the fair value of which was approximately $32.1 million. Effective in the third quarter of 2017, the Company no longer sells any product covered under the MSA. Thus, absent a change in legislation, the Company will no longer be required to make deposits to the MSA escrow account.
The Company has chosen to invest a portion of the MSA escrow, from time to time, in U.S. Government securities including TIPS, Treasury Notes, and Treasury Bonds. These investments are classified as available-for-sale and carried at fair value. Realized losses are prohibited under the MSA; any investment in an unrealized loss position will be held until the value is recovered, or until maturity. All monies at September 30, 2020 and December 31, 2019 were held in money market savings accounts.
The following shows the amount of deposits by sales year for the MSA escrow account:
Food and Drug Administration: On June 22, 2009, the Family Smoking Prevention and Tobacco Control Act (the “TCA”) authorized the FDA to immediately regulate the manufacturing, sale, and marketing of four categories of tobacco products – cigarettes, cigarette tobacco, roll-your-own tobacco, and smokeless tobacco.
Under the TCA, tobacco product user fees are assessed on six classes of regulated tobacco products. The user fees are computed using a methodology similar to the methodology used by the U.S Department of Agriculture to compute the Tobacco Transition Payment Program assessment. First, the total, annual, congressionally established user fee assessment is allocated among the various classes of tobacco products using the federal excise tax weighted market share of tobacco products subject to regulation. Then, the assessment for each class of tobacco products is divided among individual manufacturers and importers.
In August 2016, the FDA’s regulatory authority under the TCA was extended to all tobacco products not previously covered, including: (i) certain NewGen products (such as electronic cigarettes, vaporizers and e-liquids) and their components or parts (such as tanks, coils and batteries); (ii) cigars and their components or parts (such as cigar tobacco); (iii) pipe tobacco; (iv) hookah products; and (v) any other tobacco product “newly deemed” by the FDA. These “deeming regulations” apply to all products made or derived from tobacco intended for human consumption, but excluding accessories of tobacco products (such as lighters). Accordingly, the FDA has since regulated our cigar and cigar wrap products as well as our vapor products containing tobacco-derived nicotine and products intended or reasonably expected to be used to consume such e-liquids.
Under the deeming regulations, the FDA has responsibility for conducting premarket review of “new tobacco products”—defined as those products not commercially marketed in the United States as of February 15, 2007. There are three pathways for obtaining premarket authorization, including submission of a premarket tobacco product application (“PMTA”).
When the FDA initially issued the deeming regulations, it recognized that many products in the deemed categories that were already on the market qualified as “new tobacco products” and lacked a marketing order. In August 2017, the FDA issued a compliance policy (the “August 2017 Guidance”) that allowed new tobacco products to remain on the market without an FDA authorization until specified deadlines had passed. Under the August 2017 Guidance, compliance dates vary depending upon the type of application submitted, but all newly-deemed products require an application no later than August 8, 2021, for “combustible” products (e.g. cigar and pipe), and August 8, 2022, for “non-combustible” products (e.g. vapor products) with the exception of “grandfathered” products (products in commerce as of February 15, 2007) which are already authorized.
On March 27, 2018, several public health organizations filed a lawsuit (the “Maryland Lawsuit”) challenging the August 2017 Guidance. The plaintiffs asserted, among other arguments, that the modification to the deeming regulations included in the August 2017 Guidance conflicts with the TCA and exceeds FDA’s statutory authority.
The court found in favor of the plaintiffs in May 2019 and vacated the August 2017 Guidance. On July 12, 2019, the court issued its remedy order (the “Remedy Order”). Specifically, the court ordered that: (1) for all deemed new tobacco products, marketers must file applications within 10 months of the Remedy Order to continue marketing such products; (2) such a product may remain on the market pending FDA review of a timely filed application for a period not to exceed one year from the date of the application’s submission; (3) in its discretion, the FDA may enforce the premarket review requirements against such products for which marketers do not file applications within 10 months; and (4) the FDA will have the ability to exempt deemed new tobacco products from these application submission requirements for good cause, on a case-by-case basis. FDA appealed the Remedy Order and other actions adverse to the FDA; however, on May 4, 2020, the U.S. Court of Appeals for the Fourth Circuit issued a ruling dismissing the appeals in their entirety.
On March 30, 2020, citing the impacts of the worldwide COVID-19 pandemic on both FDA and industry, FDA requested a modification to the Remedy Order that would extend the May 12, 2020, deadline for filing premarket applications by 120 days to September 9, 2020. After several procedural steps, the Remedy Order was modified on April 22, 2020, to reflect the new deadline, and since then, FDA has updated relevant Guidance documents to reflect this new timeline.
In January 2020, FDA issued a Guidance document (the “January 2020 Guidance”) that stated it would be prioritizing enforcement of several categories of electronic nicotine delivery systems (“ENDS”) products: (1) flavored, cartridge-based ENDS products (other than tobacco- or menthol-flavored ENDS products); (2) ENDS products for which the manufacturer has failed to take (or is failing to take) adequate measures to prevent minors’ access; (3) ENDS products targeted to minors or whose marketing is likely to promote the use of ENDS by minors; and (4) ENDS products offered for sale after the May 12, 2020, premarket application deadline for which the manufacturer has not submitted a premarket application. The policy outlined several factors the agency would consider in its enforcement of flavored cigars going forward but did not drastically restrict those products as it had considered in its March 2019 Guidance proposal. The FDA’s policy on these and other regulated products may change or expand over time in ways not yet known and may significantly impact our products or our premarket filings.
We filed premarket filings prior to the September 9, 2020, deadline for certain of our products and intend to supplement and complete the applications within FDA’s discretionary timeline. A successful PMTA must demonstrate that the subject product is “appropriate for the protection of public health,” taking into account the effect of the marketing of the product on all sub-populations while a Substantial Equivalence Report must demonstrate that a new product either has the same characteristics as its predicate product or different characteristics, but does not raise different questions of public health. FDA has issued a number of proposed rules related to premarket filings; however, none of these rules are final yet, and their requirements may shift before being finalized. We believe we have products that meet the requisite standards and have filed premarket filings supporting a showing of the respective required standard. However, there is no assurance that the FDA’s guidance or ultimate regulation will not change, the Remedy Order will not be further altered or that unforeseen circumstances will not arise that prevent us from sufficiently supplementing or completing our applications or otherwise increase the amount of time and money we are required to spend to receive all necessary marketing orders. Although we filed many premarket applications in a timely manner, no assurance can be given that the applications will ultimately be successful. This may result in the prioritization of supplementing or completing applications for high priority SKUs in our inventory position, which could adversely impact future revenues.
In addition, we currently distribute many third-party manufactured vapor products for which we will be completely dependent on the manufacturer complying with the premarket filing requirements. There can be no assurance that these third-party products will receive a marketing order. While we will take measures to pursue regulatory compliance for our own privately-branded or proprietary vape products that compete with these third-party products, there is no assurance that such proprietary products would be as successful in the marketplace or can fully displace third-party products that are currently being distributed by us, which could adversely affect our results of operations and liquidity. For a period of time after the filing deadline, we expect there to be a lack of enforcement, which may adversely affect our ability to compete in the marketplace against those who continue to sell unauthorized products.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Recent Accounting Pronouncements |
Recent Accounting Pronouncements Adopted
In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 is intended to improve financial reporting by requiring timelier recording of credit losses on loans and other financial instruments held by financial institutions and other organizations. This ASU applies to financial assets measured at amortized cost, including loans, held-to-maturity debt securities, net investments in leases, and trade accounts receivable as well as certain off-balance sheet credit exposures, such as loan commitments. The ASU replaced the previous incurred loss impairment methodology with a methodology to reflect current expected credit losses (“CECL”) and requires consideration of a broader range of reasonable and supportable information to explain credit loss estimates. The guidance was adopted using a modified retrospective transition method through a cumulative-effect adjustment to retained earnings/(deficit) in the period of adoption. The ASU was effective for the Company beginning in the first quarter of 2020. The ASU did not have an impact to the Company’s financial statements and related disclosures.
In August 2018, the FASB issued ASU 2018-15, Intangibles — Goodwill and Other — Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. ASU 2018-15 aligns the requirements for capitalizing implementation costs in a cloud computing arrangement service contract with the requirements for capitalizing implementation costs incurred for an internal-use software license. The guidance is effective for interim and annual periods beginning after December 15, 2019, with early adoption permitted. The Company adopted ASU 2018-15 effective January 1, 2020. The ASU did not have an impact to the Company’s financial statements and related disclosures.
Recent Accounting Pronouncements Not Yet Adopted
In December 2019, the FASB issued ASU 2019-12 to simplify the accounting in ASC 740, Income Taxes. This guidance removes certain exceptions related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period, and the recognition of deferred tax liabilities for outside basis differences. This guidance also clarifies and simplifies other areas of ASC 740. This ASU will be effective beginning in the first quarter of the Company’s fiscal year 2021. Early adoption is permitted. Certain amendments in this update must be applied on a prospective basis, certain amendments must be applied on a retrospective basis, and certain amendments must be applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings/(deficit) in the period of adoption. The Company is currently evaluating the impact this ASU will have on the financial statements and related disclosures, as well as the timing of adoption.
In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40). This guidance simplifies the accounting for convertible debt instruments by reducing the number of accounting models and the number of embedded conversion features that could be recognized separately from the convertible instrument. This guidance also enhances transparency and improves disclosures for convertible instruments and earnings per share guidance. This ASU is effective for annual reporting periods beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. This update permits the use of either the modified retrospective or fully retrospective method of transition. The Company is currently evaluating the impact this ASU will have on the financial statements and related disclosures, as well as the timing of adoption.
|
Summary of Significant Accounting Policies (Tables) |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2020 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of Significant Accounting Policies [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Deposits by Sales Year for MSA Escrow Account |
The following shows the amount of deposits by sales year for the MSA escrow account:
|
Acquisitions (Tables) |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2020 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Acquisitions [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Acquisition of Solace |
In July 2019, the Company purchased the assets of E-Vape 12, Inc. and Solace Technologies LLC (“Solace”) for $9.4 million in total consideration, comprised of $7.7 million in cash, $1.1 million earn-out fair value, and $0.5 million holdback for 18 months, which was adjusted by $0.2 million for a working capital deficiency. The earn-out consists of 44,295 shares of TPB Common Stock to be issued to the former owners upon the achievement of certain annual milestones. Immediately following the acquisition, 88,582 performance based restricted stock units (“PRSUs”) with a fair value of $4.62 million were issued to former owners who became employees. See Note 15, “Share Incentive Plans”, for further details. Solace is an innovative product development company that has grown from the creator of one of the leading vape juice brands in the industry into a leader of alternative ingredients product development. The Company intends to incorporate Solace’s innovative products as well as the legacy vapor products into our Nu-X development engine. The Company completed the accounting for the acquisition during the third quarter 2020. The following purchase price and goodwill are based on the excess of the acquisition price over the estimated fair value of the tangible and intangible assets acquired:
|
Inventories (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2020 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventories [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventories |
The components of inventories are as follows:
|
Other Current Assets (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2020 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other Current Assets [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other Current Assets |
Other current assets consist of:
|
Property, Plant, and Equipment (Tables) |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2020 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Property, Plant, and Equipment [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Property, Plant and Equipment |
Property, plant, and equipment consists of:
|
Other Assets (Tables) |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2020 | ||||||||||||||||||||||||||||||||||||||||||||||
Other Assets [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||
Other Assets |
Other assets consist of:
|
Accrued Liabilities (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2020 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued Liabilities [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued Liabilities |
Accrued liabilities consist of:
|
Notes Payable and Long-Term Debt (Tables) |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2020 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes Payable and Long-Term Debt [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes Payable and Long-Term Debt |
Notes payable and long-term debt consists of the following in order of preference:
|
Leases (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2020 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Leases [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Components of Lease Expense |
The components of lease expense consisted of the following:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Operating Lease Assets and Liabilities |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Operating Lease Weighted-Average Remaining Lease Term and Discount Rate |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Maturities of Lease Liabilities |
As of September 30, 2020, and December 31, 2019, maturities of lease liabilities consisted of the following:
|
Pension and Postretirement Benefit Plans (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2020 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pension and Postretirement Benefit Plans [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Net Periodic Benefit Cost |
The following table provides the components of net periodic pension and postretirement benefit costs and total costs for the plans:
|
Share Incentive Plans (Tables) |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2020 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share Incentive Plans [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Option Activity |
There are no shares available for grant under the 2006 Plan. Stock option activity for the 2006 and 2015 Plans is summarized below:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assumptions for Options Granted Under 2015 Plan |
The following table outlines the assumptions based on the number of options granted under the 2015 Plan.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PRSU Activity |
PRSUs are restricted stock units subject to both performance-based and service-based vesting conditions. The number of shares of TPB Common Stock a recipient will receive upon vesting of a PRSU will be calculated by reference to certain performance metrics related to the Company’s performance over a five-year period. PRSUs will vest on the measurement date, which is no more than 65 days after the performance period provided the applicable service and performance conditions are satisfied. As of September 30, 2020, there are 440,132 PRSUs outstanding, all of which are unvested. The following table outlines the PRSUs granted and outstanding as of September 30, 2020.
|
Income Per Share (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2020 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Income Per Share [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Basic and Diluted Net Income per Share |
The following is a reconciliation of the numerators and denominators of the basic and diluted EPS computations of net income:
|
Segment Information (Tables) |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2020 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment Information [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Information of Reported Segments |
The tables below present financial information about reported segments:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Revenue Disaggregation - Sales Channel |
Revenues of the Smokeless and Smoking segments are primarily comprised of sales made to wholesalers while NewGen sales are made business to business and business to consumer, both online and through our corporate retail stores. NewGen net sales are broken out by sales channel below.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Net Sales - Domestic vs. Foreign |
The following table shows a breakdown of consolidated net sales between domestic and foreign customers.
|
Description of Business and Basis of Presentation (Details) |
9 Months Ended |
---|---|
Sep. 30, 2020
Segment
Outlet
| |
Description of Business and Basis of Presentation [Abstract] | |
Number of reportable segments | Segment | 3 |
Number of retail outlets in North America | Outlet | 210,000 |
Summary of Significant Accounting Policies, Shipping Costs (Details) - USD ($) $ in Millions |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2020 |
Sep. 30, 2019 |
Sep. 30, 2020 |
Sep. 30, 2019 |
|
Shipping Costs [Abstract] | ||||
Shipping costs | $ 5.3 | $ 4.4 | $ 17.4 | $ 13.6 |
Summary of Significant Accounting Policies, Derivative Instruments (Details) - Maximum [Member] |
9 Months Ended |
---|---|
Sep. 30, 2020 | |
Derivative Instruments [Abstract] | |
Percentage of anticipated purchases of inventory that may be hedged | 100.00% |
Term of hedge | 12 months |
Percentage of non-inventory purchases that may be hedged | 90.00% |
Summary of Significant Accounting Policies, Master Settlement Agreement (Details) - USD ($) $ in Thousands |
9 Months Ended | |
---|---|---|
Sep. 30, 2020 |
Dec. 31, 2019 |
|
Master Settlement Agreement [Abstract] | ||
Term for restricted withdrawal of principal from MSA escrow account | 25 years | |
Cost | $ 32,100 | $ 32,100 |
Estimated fair value | 32,100 | 32,100 |
Master Settlement Agreement Escrow Account by Sales Year [Abstract] | ||
1999 | 211 | 211 |
2000 | 1,017 | 1,017 |
2001 | 1,673 | 1,673 |
2002 | 2,271 | 2,271 |
2003 | 4,249 | 4,249 |
2004 | 3,714 | 3,714 |
2005 | 4,553 | 4,553 |
2006 | 3,847 | 3,847 |
2007 | 4,167 | 4,167 |
2008 | 3,364 | 3,364 |
2009 | 1,619 | 1,619 |
2010 | 406 | 406 |
2011 | 193 | 193 |
2012 | 199 | 199 |
2013 | 173 | 173 |
2014 | 143 | 143 |
2015 | 101 | 101 |
2016 | 91 | 91 |
2017 | 83 | 83 |
Total | $ 32,074 | $ 32,074 |
Summary of Significant Accounting Policies, Food and Drug Administration (Details) |
9 Months Ended |
---|---|
Sep. 30, 2020
Pathway
Class
Category
| |
Food and Drug Administration [Abstract] | |
Number of categories of tobacco products regulated by the FDA | Category | 4 |
Number of classes of regulated tobacco products on which user fees are assessed | Class | 6 |
Number of pathways for obtaining premarket authorization | Pathway | 3 |
Period deemed new tobacco products may remain on the market pending FDA review | 1 year |
Application period for deemed new tobacco products | 10 months |
Proposed extension period for filing premarket applications | 120 days |
Acquisitions, SDI Reorganization (Details) $ in Thousands |
3 Months Ended | 9 Months Ended | |
---|---|---|---|
Jul. 16, 2020
USD ($)
shares
|
Sep. 30, 2020
USD ($)
|
Sep. 30, 2020
USD ($)
|
|
Acquisitions [Abstract] | |||
Common Stock conversation ratio | 0.52095 | ||
Total consideration for asset purchase | $ 236,000 | ||
Common Stock issued (in shares) | shares | 7,934,704 | ||
Common Stock issued | $ 234,300 | ||
Common Stock acquired | $ 236,000 | ||
Common Stock acquired (in shares) | shares | 8,178,918 | ||
Common Stock retired (in shares) | shares | 244,214 | ||
Common Stock retired | $ 1,737 | $ 1,737 | |
Accumulated Earnings (Deficit) [Member] | |||
Acquisitions [Abstract] | |||
Common Stock retired | $ 1,700 | $ 1,735 | $ 1,735 |
Acquisitions, Durfort Holdings (Details) - Durfort [Member] - USD ($) $ in Millions |
1 Months Ended | 9 Months Ended |
---|---|---|
Jun. 30, 2020 |
Sep. 30, 2020 |
|
Acquisitions [Abstract] | ||
Total consideration transferred | $ 47.7 | |
Cash paid for acquisition | 37.7 | |
Capitalized transaction costs | 1.7 | |
Issuance of promissory note | 10.0 | |
Master Distribution Agreement [Member] | ||
Acquisitions [Abstract] | ||
Finite-lived intangible asset acquired | 5.5 | |
Finite-lived intangible asset acquired, life | 15 years | |
Intellectual Property [Member] | ||
Acquisitions [Abstract] | ||
Indefinite-lived intangible asset acquired | $ 42.2 |
Inventories (Details) - USD ($) $ in Thousands |
Sep. 30, 2020 |
Dec. 31, 2019 |
---|---|---|
Inventories [Abstract] | ||
Raw materials and work in process | $ 7,484 | $ 7,050 |
Leaf tobacco | 35,798 | 32,763 |
Other | 350 | 989 |
Gross Inventory | 78,939 | 76,731 |
LIFO reserve | (5,596) | (5,752) |
Net Inventory | 73,343 | 70,979 |
Inventory valuation allowance | 13,400 | 21,500 |
Smokeless Products [Member] | ||
Inventories [Abstract] | ||
Finished goods | 7,467 | 5,680 |
Smoking Products [Member] | ||
Inventories [Abstract] | ||
Finished goods | 8,996 | 13,138 |
NewGen Products [Member] | ||
Inventories [Abstract] | ||
Finished goods | $ 18,844 | $ 17,111 |
Other Current Assets (Details) - USD ($) $ in Thousands |
Sep. 30, 2020 |
Dec. 31, 2019 |
---|---|---|
Other Current Assets [Abstract] | ||
Inventory deposits | $ 6,214 | $ 4,012 |
Insurance deposit | 3,000 | 0 |
Prepaid taxes | 948 | 3,673 |
Other | 10,781 | 8,430 |
Total | $ 20,943 | $ 16,115 |
Property, Plant, and Equipment (Details) - USD ($) $ in Thousands |
Sep. 30, 2020 |
Dec. 31, 2019 |
---|---|---|
Property, Plant and Equipment [Abstract] | ||
Gross property, plant and equipment | $ 30,599 | $ 28,262 |
Accumulated depreciation | (16,596) | (14,446) |
Net property, plant and equipment | 14,003 | 13,816 |
Land [Member] | ||
Property, Plant and Equipment [Abstract] | ||
Gross property, plant and equipment | 22 | 22 |
Buildings and Improvements [Member] | ||
Property, Plant and Equipment [Abstract] | ||
Gross property, plant and equipment | 2,750 | 2,655 |
Leasehold Improvements [Member] | ||
Property, Plant and Equipment [Abstract] | ||
Gross property, plant and equipment | 3,749 | 2,567 |
Machinery and Equipment [Member] | ||
Property, Plant and Equipment [Abstract] | ||
Gross property, plant and equipment | 15,306 | 14,516 |
Furniture and Fixtures [Member] | ||
Property, Plant and Equipment [Abstract] | ||
Gross property, plant and equipment | $ 8,772 | $ 8,502 |
Other Assets (Details) - USD ($) $ in Thousands |
Sep. 30, 2020 |
Dec. 31, 2019 |
---|---|---|
Other Assets [Abstract] | ||
Equity investments | $ 5,421 | $ 5,421 |
Pension assets | 0 | 1,686 |
Other | 3,300 | 3,566 |
Total | $ 8,721 | $ 10,673 |
Accrued Liabilities (Details) - USD ($) $ in Thousands |
Sep. 30, 2020 |
Dec. 31, 2019 |
||
---|---|---|---|---|
Accrued Liabilities [Abstract] | ||||
Accrued payroll and related items | $ 6,332 | $ 5,267 | ||
Customer returns and allowances | 5,264 | 6,160 | ||
Taxes payable | 3,117 | 705 | ||
Lease liabilities | [1] | 3,227 | 2,218 | |
Accrued interest | 986 | 1,909 | ||
Other | 13,083 | 10,261 | ||
Total | $ 32,009 | $ 26,520 | ||
|
Notes Payable and Long-Term Debt, 2018 Credit Facility (Details) $ in Millions |
Mar. 07, 2018
USD ($)
|
---|---|
2018 Credit Facility [Member] | |
Notes Payable and Long-Term Debt [Abstract] | |
Secured credit facility | $ 250 |
Additional borrowing capacity under accordion feature | 40 |
2018 First Lien Term Loan [Member] | |
Notes Payable and Long-Term Debt [Abstract] | |
Face amount | 160 |
2018 Revolving Credit Facility [Member] | |
Notes Payable and Long-Term Debt [Abstract] | |
Maximum borrowing capacity | 50 |
2018 Second Lien Term Loan [Member] | |
Notes Payable and Long-Term Debt [Abstract] | |
Face amount | $ 40 |
Notes Payable and Long-Term Debt, 2018 Second Lien Credit Facility (Details) - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | |||
---|---|---|---|---|---|
Sep. 30, 2020 |
Sep. 30, 2019 |
Jun. 30, 2019 |
Sep. 30, 2020 |
Sep. 30, 2019 |
|
Notes Payable and Long-Term Debt [Abstract] | |||||
Loss on extinguishment of debt | $ 0 | $ (1,158) | $ 0 | $ (1,308) | |
2018 Second Lien Term Loan [Member] | |||||
Notes Payable and Long-Term Debt [Abstract] | |||||
Maturity date | Mar. 07, 2024 | ||||
Payment of term loan | 35,500 | $ 4,500 | |||
Loss on extinguishment of debt | $ (1,100) | $ (200) | |||
2018 Second Lien Term Loan [Member] | LIBOR [Member] | |||||
Notes Payable and Long-Term Debt [Abstract] | |||||
Margin on variable rate | 7.00% |
Notes Payable and Long-Term Debt, Promissory Note (Details) - Promissory Note [Member] $ in Millions |
9 Months Ended | |
---|---|---|
Sep. 30, 2020
USD ($)
Intallment
|
Jun. 10, 2020
USD ($)
|
|
Notes Payable and Long-Term Debt [Abstract] | ||
Face amount | $ 10.0 | |
Interest rate | 7.50% | |
Number of installment payments | Intallment | 2 | |
Required payment | $ 5.0 | |
Minimum [Member] | ||
Notes Payable and Long-Term Debt [Abstract] | ||
Term of note | 18 months | |
Maximum [Member] | ||
Notes Payable and Long-Term Debt [Abstract] | ||
Term of note | 36 months |
Notes Payable and Long-Term Debt, Unsecured Loan (Details) - Unsecured Loan [Member] - USD ($) $ in Millions |
9 Months Ended | |
---|---|---|
Sep. 30, 2020 |
Apr. 17, 2020 |
|
Notes Payable and Long-Term Debt [Abstract] | ||
Face amount | $ 7.5 | |
Maturity date | Apr. 17, 2022 | |
Interest rate | 1.00% |
Notes Payable and Long-Term Debt, Note Payable - IVG (Details) - Note Payable - IVG [Member] - USD ($) $ in Thousands |
9 Months Ended | ||
---|---|---|---|
Sep. 30, 2020 |
Sep. 30, 2019 |
Sep. 30, 2018 |
|
Notes Payable and Long-Term Debt [Abstract] | |||
Face amount | $ 4,000 | ||
Interest rate | 6.00% | ||
Maturity date | Mar. 05, 2020 | ||
Payment of note | $ 4,240 | $ 0 |
Leases (Details) $ in Thousands |
3 Months Ended | 9 Months Ended | |||||||
---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2020
USD ($)
Agreement
|
Sep. 30, 2019
USD ($)
|
Sep. 30, 2020
USD ($)
|
Sep. 30, 2019
USD ($)
|
Dec. 31, 2019
USD ($)
|
|||||
Components of Lease Expense [Abstract] | |||||||||
Variable lease cost | [1] | $ 96 | $ 259 | $ 452 | $ 629 | ||||
Short-term lease cost | 11 | 31 | 120 | 120 | |||||
Sublease income | (30) | (30) | (90) | (80) | |||||
Total operating lease cost | 945 | $ 996 | 2,812 | $ 2,989 | |||||
Assets [Abstract] | |||||||||
Right of use assets | 19,064 | 19,064 | $ 12,130 | ||||||
Liabilities [Abstract] | |||||||||
Current lease liabilities | [2] | 3,227 | 3,227 | 2,218 | |||||
Long-term lease liabilities | 17,073 | 17,073 | 11,067 | ||||||
Total lease liabilities | $ 20,300 | $ 20,300 | 13,285 | ||||||
Weighted-Average Remaining Lease Term and Discount Rate [Abstract] | |||||||||
Weighted-average remaining lease term - operating leases | 7 years 4 months 24 days | 8 years 7 months 6 days | 7 years 4 months 24 days | 8 years 7 months 6 days | |||||
Weighted-average discount rate - operating leases | 4.93% | 6.47% | 4.93% | 6.47% | |||||
Maturities of Lease Liabilities [Abstract] | |||||||||
2020 | $ 859 | $ 859 | |||||||
2021/2020 | 4,229 | 4,229 | 2,924 | ||||||
2022/2021 | 3,836 | 3,836 | 2,730 | ||||||
2023/2022 | 3,478 | 3,478 | 2,165 | ||||||
2024/2023 | 2,418 | 2,418 | 1,782 | ||||||
2024 | 1,028 | ||||||||
Years thereafter | 9,484 | 9,484 | |||||||
Years thereafter | 6,297 | ||||||||
Total lease payments | 24,304 | 24,304 | 16,926 | ||||||
Less: Imputed interest | 4,004 | 4,004 | 3,641 | ||||||
Total lease liabilities | $ 20,300 | 20,300 | $ 13,285 | ||||||
Number of new lease agreements | Agreement | 1 | ||||||||
Additional lease liability | $ 6,600 | 6,600 | |||||||
Cost of Sales [Member] | |||||||||
Components of Lease Expense [Abstract] | |||||||||
Operating lease cost | 225 | $ 225 | 683 | $ 649 | |||||
Selling, General and Administrative [Member] | |||||||||
Components of Lease Expense [Abstract] | |||||||||
Operating lease cost | $ 643 | $ 511 | $ 1,647 | $ 1,671 | |||||
|
Income Taxes (Details) - USD ($) $ in Millions |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2020 |
Sep. 30, 2019 |
Sep. 30, 2020 |
Sep. 30, 2019 |
|
Income Taxes [Abstract] | ||||
Effective income tax rate | 18.90% | 26.30% | 22.90% | 21.20% |
Income tax deduction related to exercise of stock options | $ 0.0 | $ 0.1 | $ 0.9 | $ 4.6 |
Income tax benefit related to valuation release | $ (0.6) | $ (0.6) |
Pension and Postretirement Benefit Plans (Details) - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2020 |
Sep. 30, 2019 |
Sep. 30, 2020 |
Sep. 30, 2019 |
|
Pension Benefits [Member] | ||||
Plan Contributions [Abstract] | ||||
Expected contributions in 2020 | $ 0 | $ 0 | ||
Net Periodic Benefit Cost [Abstract] | ||||
Service cost | 0 | $ 26 | 0 | $ 78 |
Interest cost | 0 | 130 | 190 | 390 |
Expected return on plan assets | 0 | (161) | (322) | (484) |
Amortization of (gains) losses | 0 | 36 | 72 | 110 |
Settlement and curtailment loss | 1,188 | 0 | 1,188 | 0 |
Net periodic benefit cost (income) | 1,188 | 31 | 1,128 | 94 |
Postretirement Benefits [Member] | ||||
Net Periodic Benefit Cost [Abstract] | ||||
Service cost | 0 | 0 | 0 | 0 |
Interest cost | 0 | 25 | 0 | 76 |
Expected return on plan assets | 0 | 0 | 0 | 0 |
Amortization of (gains) losses | 0 | (41) | (131) | (125) |
Settlement and curtailment loss | 0 | 0 | 0 | 0 |
Net periodic benefit cost (income) | $ 0 | $ (16) | $ (131) | $ (49) |
Share Incentive Plans, Assumptions for Options Granted Under 2006 Plan (Details) - 2006 Plan [Member] - Stock Options [Member] |
9 Months Ended |
---|---|
Sep. 30, 2020
$ / shares
shares
| |
Share Incentive Plans [Abstract] | |
Expected life | 10 years |
Exercise Price $3.83 [Member] | |
Share Incentive Plans [Abstract] | |
Number of options (in shares) | shares | 272,681 |
Exercise price (in dollars per share) | $ 3.83 |
Number of options exercisable (in shares) | shares | 272,681 |
Remaining lives | 2 years 11 months 12 days |
Expected life | 10 years |
Exercise price (in dollars per share) | $ 3.83 |
Risk free interest rate | 3.57% |
Expected volatility | 40.00% |
Dividend yield | 0.00% |
Fair value at grant date (in dollars per share) | $ 2.17 |
Share Incentive Plans, Compensation Expense Related to Options (Details) - USD ($) $ in Millions |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2020 |
Sep. 30, 2019 |
Sep. 30, 2020 |
Sep. 30, 2019 |
|
Compensation Expense [Abstract] | ||||
Compensation expense related to options | $ 0.3 | $ 0.5 | $ 0.9 | $ 1.2 |
Unrecognized compensation expense related to options | $ 0.9 | $ 0.9 | ||
Period over which unrecognized compensation expense will be expensed | 1 year 8 months 4 days |
Contingencies (Details) |
Oct. 09, 2020
Count
|
---|---|
Contingencies [Abstract] | |
Number of derivative counts filed in complaint | 2 |
Income Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2020 |
Sep. 30, 2019 |
Sep. 30, 2020 |
Sep. 30, 2019 |
|
Income Per Share [Abstract] | ||||
Consolidated net income | $ 7,796 | $ 6,274 | $ 20,298 | $ 26,039 |
Basic EPS [Abstract] | ||||
Basic weighted average shares (in shares) | 19,240,187 | 19,659,217 | 19,478,297 | 19,613,868 |
Basic EPS (in dollars per share) | $ 0.41 | $ 0.32 | $ 1.04 | $ 1.33 |
Effect of Dilutive Securities [Abstract] | ||||
Stock options (in shares) | 396,802 | 408,196 | 380,394 | 163,295 |
Diluted weighted average shares (in shares) | 19,636,989 | 20,067,413 | 19,858,691 | 19,777,163 |
Diluted EPS (in dollars per share) | $ 0.40 | $ 0.31 | $ 1.02 | $ 1.32 |
Income per Share [Abstract] | ||||
Average stock price (in dollars per share) | $ 53.86 | $ 53.86 | ||
Convertible Senior Notes [Member] | ||||
Income per Share [Abstract] | ||||
Shares excluded from calculation of diluted net income per share (in shares) | 3,202,808 | 3,202,808 |
Segment Information, Financial Information of Reportable Segments (Details) $ in Thousands |
3 Months Ended | 9 Months Ended | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2020
USD ($)
|
Sep. 30, 2019
USD ($)
|
Sep. 30, 2020
USD ($)
Segment
|
Sep. 30, 2019
USD ($)
|
Dec. 31, 2019
USD ($)
|
|||||||||||||
Segment Information [Abstract] | |||||||||||||||||
Number of reportable segments | Segment | 3 | ||||||||||||||||
Segment Information [Abstract] | |||||||||||||||||
Net sales | $ 104,174 | $ 96,800 | $ 299,826 | $ 281,767 | |||||||||||||
Gross profit | 48,307 | 42,816 | 137,830 | 124,463 | |||||||||||||
Operating income (loss) | 16,021 | 13,032 | 42,394 | 45,008 | |||||||||||||
Interest expense, net | 5,224 | 3,641 | 15,198 | 11,233 | |||||||||||||
Investment income | (3) | (265) | (128) | (527) | |||||||||||||
Loss on extinguishment of debt | 0 | 1,158 | 0 | 1,308 | |||||||||||||
Net periodic cost (income), excluding service cost | 1,188 | (12) | 997 | (34) | |||||||||||||
Income before income taxes | 9,612 | 8,510 | 26,327 | 33,028 | |||||||||||||
Capital expenditures | 1,464 | 2,096 | 3,420 | 4,060 | |||||||||||||
Depreciation and amortization | 1,286 | 1,048 | 3,786 | 2,934 | |||||||||||||
VMR settlement gain | 5,500 | ||||||||||||||||
Assets | 479,231 | 479,231 | $ 446,584 | ||||||||||||||
NewGen Products [Member] | |||||||||||||||||
Segment Information [Abstract] | |||||||||||||||||
Net sales | 38,437 | 40,391 | 120,455 | 125,756 | |||||||||||||
Corporate Unallocated [Member] | |||||||||||||||||
Segment Information [Abstract] | |||||||||||||||||
Operating income (loss) | (13,017) | [1] | (8,058) | [1] | (37,022) | [2] | (23,909) | [2] | |||||||||
Assets | [3] | 64,692 | 64,692 | 89,131 | |||||||||||||
Reportable Segments [Member] | Smokeless Products [Member] | |||||||||||||||||
Segment Information [Abstract] | |||||||||||||||||
Net sales | 29,764 | 26,187 | 87,081 | 74,907 | |||||||||||||
Gross profit | 16,042 | 13,587 | 46,580 | 39,723 | |||||||||||||
Operating income (loss) | 11,466 | 9,392 | 33,452 | 26,610 | |||||||||||||
Capital expenditures | 1,450 | 1,208 | 3,148 | 2,310 | |||||||||||||
Depreciation and amortization | 562 | 415 | 1,605 | 1,137 | |||||||||||||
Assets | 135,264 | 135,264 | 120,723 | ||||||||||||||
Reportable Segments [Member] | Smoking Products [Member] | |||||||||||||||||
Segment Information [Abstract] | |||||||||||||||||
Net sales | 35,973 | 30,222 | 92,290 | 81,104 | |||||||||||||
Gross profit | 21,263 | 16,619 | 53,066 | 43,841 | |||||||||||||
Operating income (loss) | 16,827 | 12,931 | 41,471 | 33,251 | |||||||||||||
Capital expenditures | 0 | 0 | 0 | 0 | |||||||||||||
Depreciation and amortization | 91 | 0 | 91 | 0 | |||||||||||||
Assets | 193,380 | 193,380 | 145,831 | ||||||||||||||
Reportable Segments [Member] | NewGen Products [Member] | |||||||||||||||||
Segment Information [Abstract] | |||||||||||||||||
Net sales | 38,437 | 40,391 | 120,455 | 125,756 | |||||||||||||
Gross profit | 11,002 | 12,610 | 38,184 | 40,899 | |||||||||||||
Operating income (loss) | 745 | (1,233) | 4,493 | [4] | 9,056 | [4] | |||||||||||
Capital expenditures | 14 | 888 | 272 | 1,750 | |||||||||||||
Depreciation and amortization | 633 | $ 633 | 2,090 | $ 1,797 | |||||||||||||
Assets | $ 85,895 | $ 85,895 | $ 90,899 | ||||||||||||||
|
Segment Information, Revenue Disaggregation - Sales Channel (Details) - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2020 |
Sep. 30, 2019 |
Sep. 30, 2020 |
Sep. 30, 2019 |
|
Net Sales by Sales Channel [Abstract] | ||||
Net sales | $ 104,174 | $ 96,800 | $ 299,826 | $ 281,767 |
NewGen Products [Member] | ||||
Net Sales by Sales Channel [Abstract] | ||||
Net sales | 38,437 | 40,391 | 120,455 | 125,756 |
NewGen Products [Member] | Business to Business [Member] | ||||
Net Sales by Sales Channel [Abstract] | ||||
Net sales | 26,080 | 29,981 | 81,727 | 93,182 |
NewGen Products [Member] | Business to Consumer - Online [Member] | ||||
Net Sales by Sales Channel [Abstract] | ||||
Net sales | 10,880 | 8,367 | 34,066 | 25,052 |
NewGen Products [Member] | Business to Consumer - Corporate Store [Member] | ||||
Net Sales by Sales Channel [Abstract] | ||||
Net sales | 1,389 | 2,017 | 4,500 | 7,381 |
NewGen Products [Member] | Other [Member] | ||||
Net Sales by Sales Channel [Abstract] | ||||
Net sales | $ 88 | $ 26 | $ 162 | $ 141 |
Segment Information, Net Sales - Domestic vs. Foreign (Details) - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2020 |
Sep. 30, 2019 |
Sep. 30, 2020 |
Sep. 30, 2019 |
|
Segment Information [Abstract] | ||||
Net sales | $ 104,174 | $ 96,800 | $ 299,826 | $ 281,767 |
Reportable Geographical Component [Member] | Domestic [Member] | ||||
Segment Information [Abstract] | ||||
Net sales | 100,492 | 91,236 | 290,050 | 271,521 |
Reportable Geographical Component [Member] | Foreign [Member] | ||||
Segment Information [Abstract] | ||||
Net sales | $ 3,682 | $ 5,564 | $ 9,776 | $ 10,246 |
Dividends and Share Repurchase (Details) - USD ($) $ / shares in Units, $ in Thousands |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Oct. 09, 2020 |
Sep. 30, 2020 |
Sep. 30, 2020 |
Feb. 25, 2020 |
|
Share Repurchase [Abstract] | ||||
Share repurchase program authorized amount | $ 50,000 | |||
Total number of shares repurchased (in shares) | 82,097 | 338,960 | ||
Cost of shares repurchased | $ 2,376 | $ 7,665 | ||
Average price per share (in dollars per share) | $ 28.95 | $ 22.61 | ||
Dividend Declared Q3-2020 [Member] | ||||
Dividends [Abstract] | ||||
Dividend payable, date to be paid | Oct. 09, 2020 | |||
Dividend payable, date of record | Sep. 18, 2020 | |||
Dividend Declared Q3-2020 [Member] | Subsequent Event [Member] | ||||
Dividends [Abstract] | ||||
Cash dividend paid (in dollars per share) | $ 0.05 |
Subsequent Events (Details) - Subsequent Event [Member] $ in Millions |
Oct. 27, 2020
USD ($)
|
Oct. 01, 2020
USD ($)
Store
|
---|---|---|
dosist [Member] | ||
Subsequent Events [Abstract] | ||
Investment made | $ 15.0 | |
Additional investment that can be made | $ 15.0 | |
Period to make additional investment | 12 months | |
Vapor Shark [Member] | ||
Subsequent Events [Abstract] | ||
Number of retail stores with retail assets sold | Store | 7 | |
Term to receive monthly royalties as consideration for assets sold | 4 years | |
Wild Hempettes LLC [Member] | ||
Subsequent Events [Abstract] | ||
Percentage interest acquired | 20.00% | |
Total consideration transferred | $ 2.5 | |
Percentage interest that can be acquired | 100.00% | |
Secured line of credit provided | $ 2.0 | |
Term of secured line of credit provided | 5 years |
,/8.
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MY?JHCM6F7/97YG903A4>-[+L=NJD#0DVPRY4BYD[JS/K:$M , I,1_!M)Z\;0#N8*@,A"_7..\)+BZS*H< @XT( U/
MJJ-G%HIX; 5J4TK.[7JJA/ZVJ_PG;0*U.IUY!J"(4+=YC)M6 )G0D-E7/PB+
M.2'V-%-@FDD8CCA7HITK\3M7]'#&A,V)ZP?53/-XSD;Z2D0[0H+W.W] %YG@
M)A%'$AQ) 61BMT'Q,/D>$7 84UMM$,EYC=#S>\D$-Y$XDN!("B!$."=,O/N)
MQ#&%U :2^ WDF M!-DP3B3,%
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M9 3=U2&8'D'(+%;1T$K*==T@))DGZ"2NT9:W=+4@F1%@]=Z:A+22P,&PO
M=V]R:W-H965TD"&@4>B( J.X W[@H<6;_A?!9-?RXW2$M_*[R.QXCY6;&/%
M_Q;KX]X>A3/S.54US6#NX@ JD _@+JZ%!C(>D _J>E'7+VKHU9G ,5-:$;&=
M.MAR#=4&9-]W<@99)PF-))PXEP;@A$21/9Q5P\J<\9VRP*RJI7@ ZU(Y(V2
M ,\T29Q+P DJ1/G&9.B-X@F:).G(N:)9@87+IS>GTTEL:%%F50A2R/K7DPV5C;A)
M-M[XUM=X8+ M@4-)ES;2">7U4&V8/7*,-CI@5UX&;@DB?1@JN'W<(=::GXK$
MC[@EN]NN7Z*XK4SR%ST2<3+NG;=A4H=^\H/R[&8Q.-:P@X\J,$HDV&E6)3O^
M3Z,Q-0Y5A:_J50UW@FE8Q]H_9_]!+.35ZX8&X=Y$5H\H3VS6D(KN0C7&[&Q\
ME G]LM\$=G\Q"*6K&B# B=:;:U/#7I!+RTE@X[IVVI1,SC?'Y
M6F&D7@0U?8"7PJEB6JF$(7,6LP/5C
,IO[VB0_2H
M YH,XWCNW1A':7"IZ]5N5';IH_DPG$]0*I VW]-DEPI(X7 2AJP.L--IP'+>
MRP;Q1CIR+U0\\7/3XG&7\[%>%W3]^*DD_N0GNRR.!'H9%A6$@K>=;UGM33DB
MO9_LEN:CA.ZD,);2T:R[>PA6*)OK%KX#KWP,)1EE$WI!LQ'2_@6] TJ)\5"6
M.UWU/M'L?9O>CI$^Z1JC;U6!:!(O;@H A62M5>U3655-J7+5Z3"BG[>]?@N\
M/YRD=0H+$5S+I\A^X],>H5IH8WRC[LSA?[WTTI4S>B[&Y9%O'5JTQ0,6!':-E""B;
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M'K")@\0EUM